Search Result
Results for "
S
" in MCE Product Catalog:
4836
Inhibitors & Agonists
18
Biochemical Assay Reagents
391
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
-
- HY-125845A
-
|
(S,S,S)-AHPC hydrochloride
(S,S,S)-VH032-NH2 hydrochloride
|
Ligands for E3 Ligase
|
Cancer
|
|
(S,S,S)-AHPC hydrochloride is a von Hippel-Lindau (VHL) amino building block. (S,S,S)-AHPC (Compound 27) is a ligand used as a negative control for (S,R,S)-AHPC. (S,R,S)-AHPC is the VH032-based VHL ligand used in the recruitment of the VHL protein.
|
-
- HY-17518A
-
|
(S,S)-Valifenalate
(S,S)-IR5885; (S,S)-Valiphenal
|
Fungal
|
Infection
|
|
(S,S)-Valifenalate ((S,S)-IR5885) is an acylamino acid fungicide and is used to control a wide range of fungi belonging to the class of Oomycetes. (S,S)-Valifenalate ((S,S)-IR5885) interferes with the cell-wall synthesis thus affecting the growth stages of the pathogens controlled, both outside (on the spores) or inside the plant (on the mycelium).
|
-
- HY-107409B
-
-
- HY-15344A
-
|
(S,S)-BD-AcAc 2
(S,S)-Ketone Ester
|
Others
|
Neurological Disease
|
|
(S,S)-BD-AcAc 2 ((S,S)-Ketone Ester) is a (S,S)-enantiomer of BD-AcAc 2. BD-AcAc 2 elevates the AcAc and acetone levels, thereby produces sustained ketosis and significantly delays central nervous system oxygen toxicity (CNS-OT) seizures.
|
-
- HY-128888A
-
-
- HY-50856A
-
-
- HY-W074930
-
|
(S)-Tenofovir
(S)-GS 1278; (S)-PMPA; (S)-TDF
|
HIV
HBV
|
Infection
|
|
(S)-Tenofovir ((S)-GS 1278) is the less active S-enantiomer of Tenofovir. Tenofovir is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).
|
-
- HY-14855A
-
|
(S)-Tedizolid
(S)-TR 700; (S)-DA 7157
|
Bacterial
Antibiotic
|
Infection
|
|
(S)-Tedizolid is the S-enantiomer of Tedizolid. Tedizolid is a novel oxazolidinone with activity against Gram-positive pathogens. (S)-Tedizolid is the less active isomer.
|
-
- HY-141848A
-
|
(S,S)-BMS-984923
|
mGluR
|
Neurological Disease
|
|
(S,S)-BMS-984923 is a less active (S,S)-enantiomer of BMS-984923. (S,S)-BMS-984923 shows an EC50 >1μM for mGluR5 receptor. BMS-984923 is a potent mGluR5 silent allosteric modulator.
|
-
- HY-Y1069
-
|
(S)-Malic acid
(S)-Hydroxybutanedioic acid; (S)-E 296
|
Endogenous Metabolite
|
Metabolic Disease
|
|
(S)-Malic acid ((S)-2-Hydroxysuccinic acid) is a dicarboxylic acid in naturally occurring form, contributes to the pleasantly sour taste of fruits and is used as a food additive.
|
-
- HY-14658A
-
-
- HY-107661A
-
|
S-(+)-Arundic Acid
(S)ONO-2506; (S)-2-Propyloctanoic acid
|
Others
|
Others
|
|
S-(+)-Arundic Acid ((S)ONO-2506) is the S-enantiomer of Arundic Acid. Arundic acid is an astrocyte-modulating agent, has the potential for stroke and Alzheimer’s disease research.
|
-
- HY-78131A
-
|
(S)-(+)-Ibuprofen
(S)-Ibuprofen
|
COX
|
Inflammation/Immunology
|
|
(S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC50s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects.
|
-
- HY-109854
-
-
- HY-145572B
-
-
- HY-N2037B
-
|
(S)-Higenamine
(S)-Norcoclaurine
|
Endogenous Metabolite
|
Others
|
|
(S)-Higenamine ((S)-Norcoclaurine), a S-enantiomer of Higenamine, is the entry compound in benzylisoquinoline alkaloid biosynthesis. (S)-Higenamine is produced by the condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA) by norcoclaurine synthase (NCS).
|
-
- HY-B0432B
-
-
- HY-B0352A
-
|
(S)-Mirtazapine
(S)-Org3770; (S)-6-Azamianserin
|
5-HT Receptor
|
Neurological Disease
|
|
(S)-Mirtazapine ((S)-Org3770) is a S(+)-enantiomer of Mirtazapine with pronociceptive properties in an animal model of acute thermal nociception. (S)-Mirtazapine is a stereoselective 5-HT2 receptor antagonist. (S)-Mirtazapine is metabolized by CYP2D6 and CYP1A2.
|
-
- HY-142139S
-
-
- HY-10502A
-
|
Tipifarnib (S enantiomer)
IND-58359 S enantiomer; (S)-(-)-R-115777
|
Farnesyl Transferase
|
Cancer
|
|
Tipifarnib S enantiomer is the S-enantiomer of Tipifarnib. Tipifarnib is a potent and specific farnesyltransferase (FTase) inhibitor with IC50 of 0.6 nM. Tipifarnib S enantiomer is the less active isomer.
|
-
- HY-15114
-
|
S 17092
S 17092-1
|
Prolyl Endopeptidase (PREP)
|
Neurological Disease
|
|
S 17092 (S 17092-1) is a potent cerebral prolyl-endopeptidase (PEP) inhibitor with an IC50 of 1.2 nM. S 17092 can be used for the research of memory impairment and cognitive disorders associated with cerebral aging.
|
-
- HY-N3045
-
|
(S,S)-Pisatin
|
Others
|
Others
|
|
(S,S)-Pisatin (compound 8) is a dimeric pterocarpan derivative is isolated from the grains of millettia pachyloba.
|
-
- HY-B0006B
-
-
- HY-16713A
-
-
- HY-16713
-
-
- HY-135336A
-
-
- HY-112102
-
|
(22S,23S)-Homobrassinolide
SSHB
|
Others
|
Metabolic Disease
|
|
(22S,23S)-Homobrassinolide is one of the most active brassinosteroids in inducing plant growth in various plant bioassay systems. (22S,23S)-Homobrassinolide shows Akt-dependent anabolic activity in rat skeletal muscle cells. Orally active.
|
-
- HY-W011116
-
-
- HY-18299B
-
|
(S)-Purvalanol B
(S)-NG 95
|
Others
|
Others
|
|
(S)-Purvalanol B is the S enantiomer of Purvalanol B. Purvalanol B is a cyclin-dependent kinase inhibitor.
|
-
- HY-15382
-
-
- HY-109004A
-
|
(S)-Enzaplatovir
(S)-BTA-C585
|
RSV
|
Cancer
|
|
(S)-Enzaplatovir ((S)-BTA-C585) is the S-enantiomer of Enzaplatovir. (S)-Enzaplatovir shows antiviral activities with an EC50 of 56 nM for respiratory syncytial viral (RSV) (patent WO2011094823A1 compound 77).
|
-
- HY-N2037C
-
|
(S)-Higenamine hydrobromide
(S)-Norcoclaurine hydrobromide
|
Endogenous Metabolite
|
Others
|
|
(S)-Higenamine ((S)-Norcoclaurine) hydrobromide, a S-enantiomer of Higenamine, is the entry compound in benzylisoquinoline alkaloid biosynthesis. (S)-Higenamine hydrobromide is produced by the condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA) by norcoclaurine synthase (NCS).
|
-
- HY-15452A
-
-
- HY-110024
-
|
S-14506 hydrochloride
|
5-HT Receptor
|
Neurological Disease
Others
|
|
S-14506 hydrochloride is a potent 5-HT1A agonist. S-14506 hydrochloride displays dopamine antagonist properties by blocking dopamine D2 receptors. S-14506 hydrochloride inhibits the in vivo binding of [3H]raclopride in striatum and olfactory bulbs. S-14506 hydrochloride has the potential for the research of anxiolytic agent.
|
-
- HY-W009477
-
-
- HY-105008
-
|
Secoisolariciresinol diglucoside
(S,S)-SDG; (S,S)-LGM2605
|
Others
|
Inflammation/Immunology
Neurological Disease
Cardiovascular Disease
|
|
Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects.
|
-
- HY-114072A
-
-
- HY-108263A
-
|
(S)-3-Hydroxy Midostaurin
(S)-CGP52421
|
FLT3
Drug Metabolite
|
Cancer
|
|
(S)-3-Hydroxy Midostaurin ((S)-CGP52421) is a potent kinases inhibitor with IC50 values of <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, et). (S)-3-Hydroxy Midostaurin is a minor metabolite of midostaurin (PKC412; HY-10230) undergoing by the hepatic CYP3A4 enzyme. (S)-3-Hydroxy Midostaurin has the potential for acute myeloid leukemia (AML).
|
-
- HY-10936
-
|
S 18986
|
iGluR
|
Neurological Disease
|
|
S 18986 is a selective, orally active, brain penetrant positive allosteric modulator of AMPA-type receptors. S 18986 shows cognitive enhancing properties in rodents. S 18986 activates the release of noradrenaline and acetylcholine in rat hippocampus and enhances rat memory in object-recognition tests.
|
-
- HY-B0612E
-
-
- HY-W013754
-
|
S-Hexylglutathione
|
Others
|
Others
|
|
S-Hexylglutathione is an S-substituted glutathione in which the hydrogen of the thiol has been replaced by a hexyl group. S-Hexylglutathione is also an competitive inhibitor against glutathione-S-transferase. S-Hexylglutathione can be used as an affinity chromatographic ligand for glutathione-S-transferase and glutathione peroxidase.
|
-
- HY-132247B
-
|
(S)-ErSO
|
Others
|
Cancer
|
|
(S)-ErSO is the dextrorotatory enantiomer of ErSO. (S)-ErSO is inactive in MCF-7 cells (from patent WO2020009958A1, compound (s)-105).
|
-
- HY-113884B
-
|
(S)-Coriolic acid
13(S)-HODE
|
PPAR
Mitochondrial Metabolism
|
Cancer
Inflammation/Immunology
|
|
(S)-Coriolic acid (13(S)-HODE), the product of 15-lipoxygenase (15-LOX) metabolism of linoleic acid, functions as the endogenous ligand to activate PPARγ. (S)-Coriolic acid is an important intracellular signal agent and is involved in cell proliferation and differentiation in various biological systems. (S)-Coriolic acid induces mitochondrial dysfunction and airway epithelial injury.
|
-
- HY-122123
-
|
S-6123
|
Bacterial
Antibiotic
|
Infection
|
|
S-6123 is a potent antimicrobial compound of the oxazolidinone series. S-6123 inhibits ribosomal protein synthesis without inhibiting DNA or RNA synthesis.
|
-
- HY-U00281
-
-
- HY-138862
-
-
- HY-112257
-
|
S-23
|
Androgen Receptor
|
Metabolic Disease
|
|
S-23 is an orally active selective androgen receptor modulator (SARM) with a Ki of 1.7 nM. S-23 induces androgen receptor (AR)-mediated transcriptional activation in CV-1 cells. S-23 increases prostate, seminal vesicle, and levator ani muscle weights in castrated rats.
|
-
- HY-B2137
-
-
- HY-108036A
-
|
(S)-Pro-xylane
(S)-Hydroxypropyl tetrahydropyrantriol
|
Others
|
Others
|
|
(S)-Pro-xylane ((S)-Hydroxypropyl tetrahydropyrantriol) is the S-enantiomer of Pro-xylane (HY-108036). Pro-xylane, a biologically active C-glycoside in aqueous media, acts as an activator of glycosaminoglycans (GAGs) biosynthesis.
|
-
- HY-B0827B
-
|
(S)-Dinotefuran
(S)-MTI-446
|
nAChR
Parasite
|
Infection
|
|
(S)-Dinotefuran ((S)-MTI-446), a neonicotinoid pesticide, is toxic by binding to α8 subunit of nAChR of honeybee Apis mellifera (Apis mellifera Linnaeus). (S)-Dinotefuran shows more toxic than R-dinotefuran to honeybee Apis mellifera.
|
-
- HY-19323A
-
|
(S)-Ceralasertib
(S)-AZD6738
|
ATM/ATR
|
Cancer
|
|
(S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC50 of 2.578 nM.
(S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics.
(S)-Ceralasertib is developed improving aqueous solubility and eliminates CYP3A4 time-dependent inhibition.
|
-
- HY-107728
-
-
- HY-148671
-
-
- HY-14165A
-
|
(S)-Veliflapon
(S)-BAY X 1005; (S)-DG-031
|
Leukotriene Receptor
FLAP
|
Inflammation/Immunology
|
|
(S)-Veliflapon ((S)-BAY X 1005; (S)-DG-031) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC50 values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood.
|
-
- HY-148406
-
-
- HY-136165
-
-
- HY-131959
-
-
- HY-123109
-
-
- HY-145153
-
|
S-777469
|
Cannabinoid Receptor
|
Neurological Disease
|
|
S-777469 is a selective and orally available cannabinoid type 2 receptor (CB2) agonist with a Ki of 36 nM. S-777469 significantly suppresses compound 48/80-induced scratching behavior in mice in a dose-dependent manner. S-777469 produces its antipruritic effects by inhibiting itch signal transmission through CB2 agonism.
|
-
- HY-14200
-
|
(S)-Rasagiline
TVP1022; S-PAI
|
Monoamine Oxidase
|
Neurological Disease
|
|
(S)-Rasagiline (TVP1022) is the relatively inactive S-enantiomer form of Rasagiline. Rasagiline is a highly potent selective irreversible MAO inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.
|
-
- HY-14200A
-
|
(S)-Rasagiline mesylate
TVP1022 mesylate; S-PAI mesylate
|
Monoamine Oxidase
|
Neurological Disease
|
|
(S)-Rasagiline (TVP1022) mesylate is the relatively inactive S-enantiomer form of Rasagiline mesylate. Rasagiline mesylate is a highly potent selective irreversible MAO inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.
|
-
- HY-132842A
-
|
(S)-Sunvozertinib
(S)-DZD9008
|
EGFR
Btk
|
Cancer
|
|
(S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against EGFR exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC50=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK.
|
-
- HY-132938
-
-
- HY-W009177
-
-
- HY-130798
-
-
- HY-I0775
-
-
- HY-14551B
-
|
(S)-Osanetant
(S)-SR142801
|
Neurotensin Receptor
|
Neurological Disease
|
|
(S)-Osanetant is the S-enantiomer of Osanetant. Osanetant (SR142801) is a selective NK3 receptor antagonist. Osanetant produces anxiolytic- and antidepressant-like effects and is researched for schizophrenia.
|
-
- HY-19298
-
-
- HY-136163
-
-
- HY-141016
-
-
- HY-13749C
-
-
- HY-138861A
-
-
- HY-138861
-
-
- HY-W013744
-
-
- HY-132809A
-
-
- HY-114962
-
|
S-22153
|
Melatonin Receptor
|
Neurological Disease
|
|
S-22153 is a potent melatonin receptor antagonist with EC50 values of 19 nM, 4.6 nM for hMT1 and hMT2 melatonin receptor, respectively. S-22153 has Ki values of 8.6 nM (CHO cells) and 16.3 nM (HEK cells) for hMT1, and 6.0 nM (CHO cells) and 8.2 nM (HEK cells) for hMT2. S-22153 is a specific ligand of MT1 and MT2 melatonin receptors subtypes.
|
-
- HY-139134
-
-
- HY-N10677
-
|
S-30-Hydroxygambogic acid
|
Others
|
Cancer
|
|
S-30-Hydroxygambogic acid is polyprenylated xanthone epimer that can be isolated from gamboges of Garcinia hanburyi. S-30-Hydroxygambogic acid shows cytotoxicities to Human Leukemia K562 cell lines of IC50 values of 4.49 and 3.61 μM for K562/R and K562/S, respectively. S-30-Hydroxygambogic acid can be used for the research of cancer.
|
-
- HY-78131AS
-
|
(S)-(+)-Ibuprofen D3
(S)-Ibuprofen d3
|
COX
|
Inflammation/Immunology
|
|
(S)-(+)-Ibuprofen-d3 is a deuterium labeled (S)-(+)-Ibuprofen. (S)-(+)-Ibuprofen is the S(+)-enantiomer of Ibuprofen that inhibits COX-1 and COX-2 activity with IC50s of 2.1 μM and 1.6 μM. (S)-(+)-Ibuprofen has analgesic, antiinflammatory and antipyretic effects[1][2].
|
-
- HY-152189
-
|
S19-1035
|
Others
|
Cancer
|
|
S19-1035 is a highly potent and specific aldo-keto reductase 1C3 (AKR1C3) inhibitor. S19-1035 inhibits AKR1C3 with an IC50 value of 3.04 nM. S19-1035 can be used for the research of tumor.
|
-
- HY-I0749A
-
-
- HY-16657A
-
|
(S,S)-TAPI-1
|
MMP
|
Cancer
Inflammation/Immunology
|
|
(S,S)-TAPI-1 is an isomer of TAPI-1. TAPI-1 is a TACE (ADAM17) inhibitor and blocks the shedding of several cell surface proteins. TAPI-1 is also a metalloproteinase (MMP) inhibitor.
|
-
- HY-14864A
-
-
- HY-19490A
-
|
(S)-VQW-765
(S)-AQW-051
|
nAChR
|
Neurological Disease
|
|
(S)-VQW-765 ((S)-AQW-051) is an orally active, selective and effective α7 nicotinic ACh receptor (nAChR) partial agonist. (S)-VQW-765 has potential applications in cognitive disorders related to neurological diseases, such as Alzheimer's disease or schizophrenia.
|
-
- HY-150650
-
|
S07-2001
|
Others
|
Cancer
|
|
S07-2001 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 2.08 μM. S07-2001 enhances the activity of Doxorubicin against cancer cells. S07-2001 has potential as a chemotherapeutic potentiator for cancer drug resistance.
|
-
- HY-N4200
-
-
- HY-148207
-
|
S-Benzylglutathione
|
Amino Acid Derivatives
|
Metabolic Disease
|
|
S-Benzylglutathione is a competitive glutathionase inhibitor. S-Benzylglutathione is converted to the corresponding cysteine derivatives by rat kidney microsomes. S-Benzylglutathione can be used for the research of metabolic breakdown of glutathione by the glutathionase system.
|
-
- HY-130849
-
-
- HY-Y0017
-
-
- HY-12515B
-
|
(S)-Nicardipine
(S)-YC-93 free base
|
Calcium Channel
|
Neurological Disease
Cardiovascular Disease
|
|
(S)-Nicardipine ((S)-YC-93 free base) is the less active S enantiomer of Nicardipine. Nicardipine is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure.
|
-
- HY-B1370A
-
-
- HY-B0352AS
-
|
(S)-Mirtazapine-d3
(S)-Org3770 d3; (S)-6-Azamianserin d3
|
5-HT Receptor
|
Neurological Disease
|
|
(S)-Mirtazapine-d3 is a deuterium labeled (S)-Mirtazapine. (S)-Mirtazapine is a S(+)-enantiomer of Mirtazapine with pronociceptive properties in an animal model of acute thermal nociception.(S)-Mirtazapine is a stereoselective 5-HT2 receptor antagonist. (S)-Mirtazapine is metabolized by CYP2D6 and CYP1A2[1].
|
-
- HY-103267A
-
-
- HY-130642
-
-
- HY-B0006BS
-
|
(S)-Carvedilol-d4
(S)-BM 14190-d4
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
(S)-Carvedilol-d4 is deuterium labeled (S)-Carvedilol. (S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)[1].
|
-
- HY-D1716
-
|
S0456
|
Fluorescent Dye
|
Cancer
|
|
S0456 is a near-infrared (NIR) fluorescent dye with an excitation (Ex) of 788 nM and emission (Em) of 800 nM. S0456 binds to the folate receptor (FR). S0456 can be used as a tumor-specific optical imaging agent.
|
-
- HY-150648
-
|
S07-2008
|
Others
|
Cancer
|
|
S07-2008 is a selective aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC50 of 0.16 μM. S07-2008 shows anticancer activities.
|
-
- HY-135336AS
-
-
- HY-Y1069S
-
|
(S)-Malic acid-d3
(S)-Hydroxybutanedioic acid-d3; (S)-E 296-d3
|
Endogenous Metabolite
|
Metabolic Disease
|
|
(S)-Malic acid-d3 is the deuterium labeled (S)-Malic acid. (S)-Malic acid ((S)-2-Hydroxysuccinic acid) is a dicarboxylic acid in naturally occurring form, contributes to the pleasantly sour taste of fruits and is used as a food additive[1][2].
|
-
- HY-19433A
-
-
- HY-13528
-
-
- HY-106577A
-
-
- HY-W016319
-
-
- HY-112143
-
-
- HY-B0392
-
-
- HY-130640
-
-
- HY-N1418
-
-
- HY-59121
-
-
- HY-19212
-
|
S-2474
|
COX
Lipoxygenase
|
Inflammation/Immunology
|
|
S-2474 is an inhibitor of COX-2 and 5-lipoxygenase (5-LO), with IC50s of 11 nM and 27 μM for COX-2 and COX-1 in human intact cells, and used as a nonsteroidal anti-inflammatory drug.
|
-
- HY-150644
-
|
S07-2010
|
Others
|
Cancer
|
|
S07-2010 is a potent pan-AKR1C (aldo-keto reductase family 1 member C) inhibitor, with IC50 values of 0.19, 0.36, 0.47, and 0.73 μM for AKR1C3, AKR1C4, AKR1C1 and AKR1C2, respectively. S07-2010 induces apoptosis in A549/DDP cells. S07-2010 strengthens the cytotoxicity of chemotherapeutic agents in drug-resistant cells. S07-2010 significantly inhibits the proliferation of drug-resistant cells.
|
-
- HY-106992
-
|
S 3304
|
MMP
|
Cancer
|
|
S 3304 is a novel matrix metalloproteinases (MMP) inhibitor specific for MMP-2 and MMP-9.
|
-
- HY-15464D
-
|
(S)-Gossypol (acetic acid)
(S)-(+)-Gossypol acetic acid
|
Bcl-2 Family
|
Cancer
|
|
(S)-Gossypol is the isomer of a natural product Gossypol. (S)-Gossypol binds to the BH3-binding groove of Bcl-xL and Bcl-2 proteins with high affinity.
|
-
- HY-139218
-
-
- HY-W018499
-
-
- HY-12995A
-
|
(S)-BI 665915
|
FLAP
|
Inflammation/Immunology
|
|
(S)-BI 665915 is an orally active oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 1.7 nM for FLAP binding. (S)-BI 665915 inhibits FLAP functional in human whole blood with an IC50 of 45 nM. (S)-BI 665915 demonstrates an excellent cross-species drug metabolism and pharmacokinetics (DMPK) profile and a dose-dependent inhibition of LTB4 production.
|
-
- HY-119366
-
|
S18-000003
|
ROR
|
Inflammation/Immunology
|
|
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of <30 nM towards human RORγt in competitive binding assays. S18-000003 shows selectivity for RORγt over other ROR family members (IC50>10 μM). S18-000003 can be used for the research of psoriasis with low risk of thymic aberrations.
|
-
- HY-130847
-
-
- HY-120986
-
|
(S)-Bromoenol lactone
(S)-BEL; (S,E)-Bromoenol lactone
|
Phospholipase
|
Inflammation/Immunology
|
|
(S)-Bromoenol lactone ((S)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase A2β (iPLA2β) that inhibits the vasopressin-induced release of arachidonate from cultured rat aortic smooth muscle (A10) cells with an IC50 of 2 µM.
|
-
- HY-143430
-
|
(S)-LY3177833
|
CDK
|
Cancer
|
|
(S)-LY3177833 ((S)-Example 2) is an orally active CDC7 kinase inhibitor. (S)-LY3177833 shows broad in vitro anticancer activity.
|
-
- HY-17628
-
|
Cefiderocol
S-649266
|
Bacterial
Antibiotic
|
Infection
|
|
Cefiderocol (S-649266) is a siderophore cephalosporin which has a potent activity against a broad range of aerobic Gram-negative bacterial species with MIC50s of 2 μg/mL or less.
|
-
- HY-143430A
-
|
(S)-LY3177833 hydrate
|
CDK
|
Cancer
|
|
(S)-LY3177833 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor. (S)-LY3177833 hydrate shows broad in vitro anticancer activity.
|
-
- HY-147192
-
-
- HY-14423
-
-
- HY-101445B
-
|
(S)-Trolox
|
Others
|
Neurological Disease
|
|
(S)-Trolox is an analogue of vitamin E, in which the phytyl chain is replaced with a carboxyl group. (S)-Trolox is frequently used as a model compound for studies of structural features, as well as a standard for evaluation of antioxidant activity. (S)-Trolox has potent and specific neuroprotective and antioxidant effects.
|
-
- HY-112472
-
|
S3969
|
Sodium Channel
|
Metabolic Disease
|
|
S3969 is a potent and reversible activator of the human epithelial sodium channel (hENaC). The apparent EC50 for S3969 activation of hENaC is 1.2 μm.
|
-
- HY-14147A
-
|
(S)-Renzapride
(S)-BRL 24924
|
5-HT Receptor
|
Metabolic Disease
|
|
(S)-Renzapride ((S)-BRL 24924) is the isomer of HY-14147 Renzapride. Renzapride is a 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride also is a 5HT2b and 5HT3 receptor antagonist. Renzapride can be used for constipation predominant irritable bowel syndrome (C-IBS) study.
|
-
- HY-N8115
-
-
- HY-N10392
-
|
(S)-Erypoegin K
|
Apoptosis
|
Cancer
|
|
(S)-Erypoegin K is a potent anticancer agent. (S)-Erypoegin K shows potent anti-proliferative activity against HL-60 cells. (S)-Erypoegin K induces apoptosis.
|
-
- HY-78093A
-
-
- HY-30215
-
-
- HY-113471A
-
|
(S)-(-)-Perillic acid
|
Apoptosis
Bacterial
|
Cancer
Infection
|
|
(S)-(-)-Perillic acid is a terpenoid plant extract with antimicrobial and anticancer activities. (S)-(-)-Perillic acid induces cell apoptosis and cell cycle arrest, and increases the levell of Bax, Bcl2, p21 and caspase-3 proteins. (S)-(-)-Perillic acid can be used for cancer and infection research.
|
-
- HY-W040233S
-
-
- HY-15532B
-
|
SCH900776 (S-isomer)
MK-8776 S-isomer
|
Others
|
Cancer
|
|
SCH900776 S-isomer is the S-isomer of SCH900776. SCH900776 is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with IC50 of 3 nM.
|
-
- HY-139611B
-
-
- HY-110277
-
|
S2101
|
Histone Demethylase
|
Cancer
|
|
S2101 is a lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 0.99 μM, Ki of 0.61 μM and Kinact/Ki of 4560 M/s.
|
-
- HY-79334
-
-
- HY-P99050
-
-
- HY-14258
-
|
Escitalopram
(S)-Citalopram; (S)-(+)-Citalopram
|
Serotonin Transporter
|
Neurological Disease
|
|
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression.
|
-
- HY-126057AS
-
-
- HY-131390
-
-
- HY-112818
-
-
- HY-B0196B
-
|
(S)-Venlafaxine
|
Serotonin Transporter
|
Cancer
|
|
(S)-Venlafaxine is the (S)-configuration of Venlafaxine. Venlafaxine is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant agent.
|
-
- HY-N0603
-
-
- HY-B1184A
-
|
(S)-Mephenytoin
(+)-Mephenytoin
|
Cytochrome P450
|
Neurological Disease
|
|
(S)-Mephenytoin ((+)-Mephenytoin) is an anticonvulsive agent. (S)-Mephenytoin is a substrate of the cytochrome P450 (CYP) isoform CYP2C19. (S)-Mephenytoin can be used for the analysis of cytochrome P450 metabolism.
|
-
- HY-N2176
-
-
- HY-147025
-
-
- HY-B1122
-
-
- HY-22385B
-
-
- HY-W009343
-
-
- HY-I0115
-
-
- HY-136593
-
|
(S)-3-(4-Hydroxyphenyl)-2-hydroxypropionic acid
(S)-3-(4-Hydroxyphenyl)lactic acid
|
Others
|
Others
|
|
(S)-3-(4-Hydroxyphenyl)-2-hydroxypropionic acid (compound 1) is a metabolite isolated from the culture medium of Leuconostoc mesenteroides. (S)-3-(4-Hydroxyphenyl)-2-hydroxypropionic acid has high DPPH radical-scavenging activities and antioxidative activities.
|
-
- HY-115722
-
|
(S)-(-)-MRJF22
|
Others
|
Cancer
|
|
(S)-(-)-MRJF22 is haloperidol metabolite II valproate ester. (S)-(-)-MRJF22 exhibits the high antimigratory effects in endothelial and tumor cells. (S)-(-)-MRJF22 is a potential multifunctional agent against uveal melanoma.
|
-
- HY-U00222
-
-
- HY-130233
-
|
S516
|
Microtubule/Tubulin
|
Cancer
|
|
S516 (Compound 22) is an active metabolite of CKD-516 and a potent tubulin polymerization inhibitor with an IC50 of 4.29 μM. S516 has marked antitumor activity.
|
-
- HY-110282
-
|
S3QEL-2
|
Mitochondrial Metabolism
|
Metabolic Disease
|
|
S3QEL-2, a suppressor of superoxide production from mitochondrial complex III, potently and selectively suppresses site IIIQo superoxide production (IC50=1.7 μM). S3QEL-2 does not affect oxidative phosphorylation, and normal electron flux. S3QEL-2 inhibits HIF-1α accumulation.
|
-
- HY-107004A
-
-
- HY-12210
-
|
(S)-BI-1001
|
HIV Integrase
|
Infection
|
|
(S)-BI-1001 (Compound 11) is an active S-enantiomer of BI-1001. (S)-BI-1001 exhibits antiviral potency against HIV-1 integrase with an IC50 of 28 nM, an EC50 of 450 nM and a Kd of 4.7 μM.
|
-
- HY-103267
-
-
- HY-120986S
-
-
- HY-B0371D
-
|
(S)-Terazosin
|
Adrenergic Receptor
|
Endocrinology
|
|
(S)-Terazosin is an active S-enantiomer of Terazosin. (S)-Terazosin is a potent and high-affinity α-adrenoceptor antagonist with Ki values of 3.91 nM, 0.79 nM and 1.16 nM for α1a, α1b and α1d-adrenoceptor, respectively. (S)-Terazosin also has high-affinity for α2a, α2B and α2c-adrenoceptor with Ki values of 729 nM, 3.5 nM and 46.4 nM, respectively.
|
-
- HY-136522
-
|
S2116
|
Histone Demethylase
Apoptosis
|
Cancer
|
|
S2116, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2116 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2116 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2116 significantly retardes the growth of T-ALL cells in xenotransplanted mice.
|
-
- HY-146695
-
|
S100P-IN-1
|
Others
|
Cancer
|
|
S100P-IN-1 (Compound 4) is a S100P inhibitor with an IC50 of 22.7 nM. S100P-IN-1 shows anti-metastatic effects on pancreatic cancer cells.
|
-
- HY-B0617
-
|
S-Adenosyl-L-methionine
S-Adenosyl methionine; Ademetionine; AdoMet
|
Endogenous Metabolite
|
Cancer
Inflammation/Immunology
Neurological Disease
|
|
S-Adenosyl-L-methionine (S-Adenosyl methionine) is produced endogenously from methionine and ATP by action of the enzyme methionine adenosyltransferase and is an important orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects, and has the potential for liver disease and osteoarthritis research.
|
-
- HY-N0707
-
-
- HY-I0392AS
-
-
- HY-143808S
-
-
- HY-142547S
-
-
- HY-144249S
-
-
- HY-I0392S
-
-
- HY-W009749CS
-
-
- HY-11053
-
|
S 24795
|
nAChR
|
Neurological Disease
|
|
S 24795 is a partial agonist of α7 nAChR and improves mnemonic function in aged mice for the treatment of aging-related memory disturbances.
|
-
- HY-12023
-
|
GTx-007
S-4
|
Androgen Receptor
|
Cancer
|
|
GTx-007 (S-4) is an orally active and selective nonsteroidal androgen receptor (AR) modulator (SARM) and a partial agonist, with Ki of 4 nM. GTx-007 (S-4) is identified as SARMs with potent and tissue-selective in vivo pharmacological activity.
|
-
- HY-B0573A
-
|
(S)-(-)-Propranolol hydrochloride
|
Adrenergic Receptor
|
Inflammation/Immunology
Cardiovascular Disease
|
|
(S)-(-)-Propranolol hydrochloride is a β-adrenergic receptor antagonist with log Kd values of -8.16, -9.08, and -6.93 for β1, β2, and β3, respectively. (S)-(-)-Propranolol hydrochloride the active enantiomer of propranolol and can be s used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.
|
-
- HY-B0617A
-
|
S-Adenosyl-L-methionine tosylate
S-Adenosyl methionine tosylate; Ademetionine tosylate; AdoMet tosylate
|
Endogenous Metabolite
|
Cancer
Inflammation/Immunology
Neurological Disease
|
|
S-Adenosyl-L-methionine tosylate (S-Adenosyl methionine tosylate) is produced endogenously from methionine and ATP by action of the enzyme methionine adenosyltransferase and is an important orally active methyl group donor. S-Adenosyl-L-methionine tosylate is a dietary supplement with potent antidepressant and analgesic effects, and has the potential for liver disease and osteoarthritis research.
|
-
- HY-107516
-
|
(S)-3,4-DCPG
(S)-3,4-Dicarboxyphenylglycine
|
mGluR
|
Neurological Disease
|
|
(S)-3,4-DCPG is a selective agonist of metabotropic glutamate receptor 8a (mGluR8a) with an EC50 of 31 nM in AV12-664 cells expressing human mGluR8.
|
-
- HY-B0580A
-
-
- HY-117279
-
-
- HY-14614D
-
-
- HY-125784BS
-
-
- HY-139532S
-
-
- HY-144216S
-
-
- HY-136907S
-
-
- HY-107367
-
|
Epertinib
S-22611
|
EGFR
|
Cancer
|
|
Epertinib (S-22611) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib shows potent antitumor activity.
|
-
- HY-107367A
-
|
Epertinib hydrochloride
S-22611 hydrochloride
|
EGFR
|
Cancer
|
|
Epertinib (S-22611) hydrochloride is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib hydrochloride shows potent antitumor activity.
|
-
- HY-138697
-
|
S65487
VOB560
|
Bcl-2 Family
Apoptosis
|
Cancer
|
|
S65487 (VOB560), a potent and selective BCL-2 inhibitor, is a prodrug of S55746. S65487 is also active on BCL-2 mutations, such as G101V and D103Y. S65487 has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 induces apoptosis and has anticaner activities.
|
-
- HY-138697B
-
|
S65487 hydrochloride
VOB560 hydrochloride
|
Bcl-2 Family
Apoptosis
|
Cancer
|
|
S65487 (VOB560) hydrochloride, a potent and selective Bcl-2 inhibitor, is a prodrug of S55746. S65487 hydrochloride is also active on BCL-2 mutations, such as G101V and D103Y. S65487 hydrochloride has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 hydrochloride induces apoptosis and has anticaner activities.
|
-
- HY-145835A
-
|
(S)-PERK-IN-5
|
PERK
|
Cancer
Infection
|
|
(S)-PERK-IN-5 is the S-enantiomer of PERK-IN-5. (S)-PERK-IN-5 (example 39) is a PERK inhibitor, with an IC50 of 0.101-0.250 μM.
|
-
- HY-E70043
-
-
- HY-B0130
-
-
- HY-W009392
-
-
- HY-122136
-
|
S26131
|
Melatonin Receptor
|
Neurological Disease
|
|
S26131 (compound 5) is a potent and selective MT1 melatoninergic ligand, and the Ki values are 0.5 and 112 nM for MT1 and MT2, respectively. S26131 behaves as an MT1 and MT2 antagonist.
|
-
- HY-136523
-
|
S2157
|
Histone Demethylase
Apoptosis
|
Cancer
|
|
S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2157 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2157 efficiently pass through the blood-brain barrier and can almost completely eradicate CNS leukemia in mice transplanted with T-ALL cells.
|
-
- HY-146380
-
|
S1427
|
Histone Demethylase
|
Cancer
|
|
S1427 is a tranylcypromine-derived LSD1 inhibitor with the IC50 of 390 nM and Ki of 80 nM. S1427 exhibits desirable hERG channel inhibition and microsomal stability profiles. Inhibition of LSD1 partially reduces the proliferation of cancer cells.
|
-
- HY-W019714
-
-
- HY-136163A
-
-
- HY-12598
-
|
(S)-3,5-DHPG
|
mGluR
|
Neurological Disease
|
|
(S)-3,5-DHPG is a weak, but selective group I metabotropic glutamate receptors (mGluRs) agonist with Ki values of 0.9 µM and 3.9 µM for mGluR1a and mGluR5a, respectively. (S)-3,5-DHPG exhibits anxiolytic activity in rats subjected to hypoxia.
|
-
- HY-100815A
-
-
- HY-112218
-
|
MIK665
S-64315
|
Bcl-2 Family
|
Cancer
|
|
MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 (MCL1) inhibitor. MIK665 has an IC50 of 1.81 nM for MCL1.
|
-
- HY-108625
-
|
SHA 68
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
SHA 68 is a potent and selective non-peptide neuropeptide S receptor (NPSR) antagonist with IC50s of 22.0 and 23.8 nM for NPSR Asn 107 and NPSR Ile 107, respectively. SHA 68 has limited the blood-brain barrier (BBB) penetration and the activity in neuralgia.
|
-
- HY-108572
-
|
S26948
|
PPAR
|
Metabolic Disease
Cardiovascular Disease
|
|
S26948 is a specific peroxisome proliferator-activated receptor γ (PPARγ) modulator (EC50=8.83 nM) with potent antidiabetes and antiatherogenic effects. S26948 is a specific high-affinity agonist for PPARγ.
|
-
- HY-15529
-
|
S0859
|
Na+/HCO3- Cotransporter
|
Cardiovascular Disease
|
|
S0859 is a selective, high-affinity generic Na +/HCO3 - transporter (NBC) inhibitor. S0859 reversibly inhibits NBC-mediated intracellular pH (pHi) recovery (Ki=1.7 μM, full inhibition at approximately 30 μM).
|
-
- HY-B1161A
-
|
S-Methoprene
(+)-Methoprene; (7S)-Methoprene
|
Others
|
Others
|
|
(S)-Methoprene is a juvenile hormone analogue that prohibits the ability of the insect to change from pupae to adult and is used as an insecticide.
|
-
- HY-150646
-
|
S07-2009
|
Others
|
Cancer
|
|
S07-2009 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 0.20 μM.
|
-
- HY-114176B
-
-
- HY-114176A
-
-
- HY-103225
-
-
- HY-B0612ES
-
-
- HY-111592
-
-
- HY-78327AS
-
-
- HY-U00432
-
-
- HY-100583
-
-
- HY-104003
-
-
- HY-79457
-
-
- HY-112371
-
|
(S)-CR8
|
CDK
|
Cancer
|
|
(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective CDK inhibitor with IC50s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC50 0.40 μM).
|
-
- HY-P2093
-
|
S961
|
Insulin Receptor
|
Metabolic Disease
|
|
S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
|
-
- HY-P2093B
-
|
S961 acetate
|
Insulin Receptor
|
Metabolic Disease
|
|
S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
|
-
- HY-111827
-
-
- HY-101313
-
-
- HY-138550A
-
-
- HY-150649
-
|
S07-2005 (racemic)
|
Others
|
Cancer
|
|
S07-2005 racemic is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. S07-2005 racemic has potential as a chemotherapeutic potentiator for cancer drug resistance.
|
-
- HY-148208
-
|
S-(p-Nitrobenzyl)glutathione
|
Amino Acid Derivatives
|
Metabolic Disease
|
|
S-(p-Nitrobenzyl)glutathione is a competitive glutathionase inhibitor. S-(p-Nitrobenzyl)glutathione is converted to the corresponding cysteine derivatives by rat kidney microsomes. S-(p-Nitrobenzyl)glutathione can be used for the research of metabolic breakdown of glutathione by the glutathionase system.
|
-
- HY-79491S
-
-
- HY-100504
-
|
S-methyl DM1
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin with a Kd of 0.93 μM and inhibts microtubule polymerization. S-methyl DM1 potently suppresses microtubule dynamic instability and has anticancer effects.
|
-
- HY-138551A
-
-
- HY-145287
-
|
S-MGB-234
|
DNA/RNA Synthesis
Parasite
|
Infection
|
|
S-MGB-234 is a minor groove binder of Animal African Trypanosomiasis (AAT). S-MGB-234 displays excellent in vitro activities against the principal causative organisms of AAT; Trypanosoma congolense, and Trypanosoma vivax. S-MGB-234 does not show cross-resistance with the current diamidine drugs and are not internalized via the transporters used by diamidines.
|
-
- HY-113304
-
-
- HY-108953
-
-
- HY-131284
-
|
(S)-Dehydro Venlafaxine
|
Drug Metabolite
|
Others
|
|
(S)-Dehydro Venlafaxine is an inactive S-enantiomer of Dehydro Venlafaxine. Dehydro Venlafaxine is an impurity of Venlafaxine hydrochloride. Venlafaxine hydrochloride (Wy 45030 hydrochloride) is a potent serotonin (5-HT) / norepinephrine (NE) reuptake dual inhibitor.
|
-
- HY-143216A
-
-
- HY-143216
-
-
- HY-11017AS
-
-
- HY-W040432
-
-
- HY-W008028
-
-
- HY-W005388
-
-
- HY-76962
-
-
- HY-W016363
-
-
- HY-122614
-
|
S29434
NMDPEF
|
Autophagy
|
Neurological Disease
|
|
S29434 (NMDPEF) is a potent, competitive, selective and cell-permeable inhibitor of quinone reductase 2 (QR2), with IC50s ranging from 5 to 16 nM for human QR2 at different organizational levels, and has good selectivity for QR2 over QR1. S29434 induces autophagy and inhibits QR2-mediated ROS production.
|
-
- HY-124775
-
-
- HY-137330
-
-
- HY-B1433
-
-
- HY-107647
-
|
(S)-(+)-Dimethindene maleate
|
mAChR
Histamine Receptor
|
Inflammation/Immunology
|
|
(S)-(+)-Dimethindene maleate, an enantiomer, is a potent M2-selective muscarinic receptor antagonist (pA2 = 7.86/7.74; pKi = 7.78). (S)-(+)-Dimethindene maleate shows lower affinities for the muscarinic M1 (pA2 = 6.83/6.36; pKi = 7.08), the M3 (pA2 = 6.92/6.96; pKi = 6.70) and the M4 receptors (pKi = 7.00), respectively. (S)-(+)-Dimethindene maleate also is a histamine H1 receptor antagonist (pA2 = 7.48).
|
-
- HY-13950
-
|
S186
|
Others
|
Others
|
|
S186 is a kind of sodium salts of calcium-acetylpropylamine phosphonate(APA); a new strontium-specific chelating agent.
|
-
- HY-134661
-
|
(S)-CVN424
|
GPR6
|
Neurological Disease
|
|
(S)-CVN424 is a potent G-Protein-Coupled Receptor 6 (GPR6) modulator. (S)-CVN424 has the potential for a variety of neurological and psychiatric disorders research, including Parkinson's disease.
|
-
- HY-137231B
-
|
(S)-UFR2709 hydrochloride
|
nAChR
|
Neurological Disease
|
|
(S)-UFR2709 (hydrochloride) is a competitive nAChR antagonist and displays higher affinity for α4β2 nAChRs than for α7 nAChRs. (S)-UFR2709 (hydrochloride) decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 (hydrochloride) acts as an anxiolytic agent and can be used for the study of nicotine addiction.
|
-
- HY-137231A
-
|
(S)-UFR2709
|
nAChR
|
Neurological Disease
|
|
(S)-UFR2709 is a competitive nAChR antagonist and displays higher affinity for α4β2 nAChRs than for α7 nAChRs. (S)-UFR2709 decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 acts as an anxiolytic agent and can be used for the study of nicotine addiction.
|
-
- HY-151791
-
|
(S,R,S)-AHPC-C6-PEG3-butyl-N3
|
ADC Linker
|
Others
|
|
(S,R,S)-AHPC-C6-PEG3-butyl-N3 is a click chemistry reagent containing an azide group. (S,R,S)-AHPC-C6-PEG3-butyl-N3 serves as crosslinker-E3 ligase ligand conjugate, Click reactive protein degrader building block for PROTAC research, Template for synthesis of targeted protein degrader, VH032 conjugate.
|
-
- HY-139727
-
|
S(-)-Bisoprolol
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
S(-)-Bisoprolol is a S(-)-enantiomer of Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
|
-
- HY-W010277
-
-
- HY-18313
-
-
- HY-12835
-
-
- HY-103504
-
-
- HY-129941
-
-
- HY-129941A
-
-
- HY-142163
-
|
S62798
|
Others
|
Cardiovascular Disease
|
|
S62798 is a selective and potent inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) with an IC50 value of 6 mM.
|
-
- HY-126456
-
-
- HY-144117A
-
|
(S)-GFB-12811
|
CDK
|
Cancer
Neurological Disease
|
|
(S)-GFB-12811 (compound 596) is a potent and selective CDK5 inhibitor, with an IC50 value less than 10 nM. (S)-GFB-12811 can be used in the research of cell cycle progression, neuronal development, tumorigenesis.
|
-
- HY-100406
-
|
(S)-MCPG
(+)-MCPG
|
mGluR
|
Neurological Disease
|
|
(S)-MCPG ((+)-MCPG) is a potent group I/II metabotropic glutamate receptor (mGluRs) antagonist and the active isomer of (RS)-MCPG (HY-100371). (S)-MCPG can be used for the study of the function of mGluRs in spatial learning.
|
-
- HY-100549
-
|
(S)-Crizotinib
|
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
(S)-Crizotinib is a potent and selective MTH1 (mutT homologue) inhibitor with an IC50 of 330 nM. (S)-Crizotinib disrupts nucleotide pool homeostasis via MTH1 inhibition, induces an increase in DNA single strand breaks, activates DNA repair in human colon carcinoma cells, and effectively suppresses tumour growth in animal models.
|
-
- HY-139727A
-
|
S(-)-Bisoprolol fumarate
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
S(-)-Bisoprolol fumarate is a S(-)-enantiomer of Bisoprolol fumarate. Bisoprolol fumarate is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
|
-
- HY-113486S
-
|
(S)-Lathosterol-d4
|
Endogenous Metabolite
|
|
|
(S)-Lathosterol-d4 is the deuterium labeled (S)-Lathosterol. Lathosterol is a cholesterol-like molecule. Serum Lathosterol concentration is an indicator of whole-body cholesterol synthesis[1].
|
-
- HY-103603B
-
-
- HY-112543
-
|
S119-8
|
Influenza Virus
|
Infection
|
|
S119-8 is a broad spectrum inhibitor of influenza A and B viruses, showing activity against multiple influenza B viruses and an oseltamivir-resistant influenza A virus, but does not inhibit a non-influenza virus, vesicular stomatitis nirus (VSV).
|
-
- HY-14258A
-
|
Escitalopram oxalate
(S)-Citalopram oxalate; (S)-(+)-Citalopram oxalate
|
Serotonin Transporter
|
Neurological Disease
|
|
Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression.
|
-
- HY-B2188
-
-
- HY-136008A
-
-
- HY-139345
-
-
- HY-76996S1
-
-
- HY-146561
-
|
S-HP210
|
Glucocorticoid Receptor
NF-κB
|
Inflammation/Immunology
|
|
S-HP210 is a potent and selective glucocorticoid receptor (GR) with an IC50 value of 1.92 μM for NF-κB transrepression (TR). S-HP210 represses the LPS-induced transcription of a variety of proinflammatory genes such as IL-1β, IL-6 and COX-2. S-HP210 is nontoxic at effective doses against mouse fibroblasts 3T3 cells.
|
-
- HY-Z0424
-
-
- HY-139583
-
-
- HY-128736
-
-
- HY-126068
-
-
- HY-15124
-
-
- HY-112078
-
|
(S,R,S)-AHPC-Me
VHL ligand 2; E3 ligase Ligand 1A
|
Ligands for E3 Ligase
|
Cancer
|
|
(S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC50 <1 nM.
|
-
- HY-N0095
-
|
(S)-10-Hydroxycamptothecin
10-HCPT; 10-Hydroxycamptothecin
|
Topoisomerase
Apoptosis
|
Cancer
|
|
(S)-10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) is a DNA topoisomerase I inhibitor of isolated from the Chinese plant Camptotheca accuminata. (S)-10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S)-10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia treatment.
|
-
- HY-113380
-
-
- HY-12499
-
-
- HY-W013201
-
-
- HY-P2093A
-
|
S961 TFA
|
Insulin Receptor
|
Metabolic Disease
|
|
S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
|
-
- HY-100822A
-
|
(S)-(-)-HA 966
(-)-HA 966
|
iGluR
|
Neurological Disease
|
|
(S)-(-)-HA 966 ((-)-HA 966), a γ-Hydroxybutyrate-like agent, is weakly active as an NMDA-receptor antagonist. (S)-(-)-HA 966 possesses muscle relaxant action and prevents enhanced mesocorticolimbic dopamine metabolism and behavioral correlates of restraint stress, conditioned fear.
|
-
- HY-78828A
-
-
- HY-12965
-
-
- HY-143312C
-
|
(S)-V-0219
|
GLP Receptor
|
Metabolic Disease
|
|
(S)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice.
|
-
- HY-P3814
-
-
- HY-W009682
-
-
- HY-138697A
-
|
S65487 sulfate
VOB560 sulfate
|
Bcl-2 Family
Apoptosis
|
Cancer
|
|
S65487 (VOB560) sulfate, a potent and selective Bcl-2 inhibitor, is a prodrug of S55746. S65487 sulfate is also active on BCL-2 mutations, such as G101V and D103Y. S65487 sulfate has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 sulfate induces apoptosis and has anticaner activities.
|
-
- HY-117288
-
|
S55746
BCL201
|
Bcl-2 Family
|
Cancer
|
|
S55746 (BCL201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity.
|
-
- HY-117288A
-
|
S55746 hydrochloride
BCL201 hydrochloride
|
Bcl-2 Family
|
Cancer
|
|
S55746 hydrochloride (BCL201 hydrochloride) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 hydrochloride (BCL201 hydrochloride) has antitumor activity with low toxicity.
|
-
- HY-115682
-
-
- HY-W128028
-
-
- HY-59135
-
-
- HY-W008077
-
-
- HY-W012707
-
-
- HY-W042478
-
-
- HY-59140
-
-
- HY-30220
-
-
- HY-153100A
-
|
(S)-mchm5U
|
Others
|
Others
|
|
(S)-mchm5U is a hydroxylated form of mcm5U, may be present in tRNA from the silkworm Bombyx mori. (S)-mchm5U may be present also in mammalian tRNA, and that the ALKBH8 oxygenase could be responsible for its formation. (S)-mchm5U can be used for RNA modification synthesis.
|
-
- HY-120973A
-
-
- HY-Y1069S3
-
-
- HY-100741
-
|
S63845
|
Bcl-2 Family
|
Cancer
|
|
S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor with a Kd of 0.19 nM for human MCL1.
|
-
- HY-123450
-
|
S116836
|
Bcr-Abl
Apoptosis
PDGFR
|
Cancer
|
|
S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies.
|
-
- HY-133158S
-
-
- HY-144403S
-
-
- HY-42424
-
|
(S,R,S)-AHPC-Me hydrochloride
VHL ligand 2 hydrochloride; E3 ligase Ligand 1
|
Ligands for E3 Ligase
|
Cancer
|
|
(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me hydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC50 <1 nM.
|
-
- HY-42424A
-
|
(S,R,S)-AHPC-Me dihydrochloride
VHL ligand 2 dihydrochloride; E3 ligase Ligand 1 dihydrochloride
|
Ligands for E3 Ligase
|
Cancer
|
|
(S,R,S)-AHPC-Me dihydrochloride (VHL ligand 2 dihydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me dihydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC50 <1 nM.
|
-
- HY-W048286
-
-
- HY-125845
-
|
(S,R,S)-AHPC
VH032-NH2; VHL ligand 1
|
Ligands for E3 Ligase
|
Cancer
|
|
(S,R,S)-AHPC (VH032-NH2) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC50 of 1.11 μM in Ba/F3 cells.
|
-
- HY-101763A
-
|
(S,R,S)-AHPC hydrochloride
VH032-NH2 hydrochloride; VHL ligand 1 hydrochloride
|
Ligands for E3 Ligase
|
Cancer
|
|
(S,R,S)-AHPC (VH032-NH2) hydrochloride is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC hydrochloride can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC50 of 1.11 μM in Ba/F3 cells.
|
-
- HY-131387
-
-
- HY-113304A
-
-
- HY-136184
-
-
- HY-13818
-
|
Stattic
|
STAT
Apoptosis
|
Cancer
Inflammation/Immunology
|
|
Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727). Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice.
|
-
- HY-126145
-
-
- HY-137451
-
-
- HY-W016644
-
-
- HY-138553A
-
-
- HY-N0707S
-
|
(S)-Indoximod-d3
1-Methyl-L-tryptophan-d3; (S)-NLG-8189-d3
|
Indoleamine 2,3-Dioxygenase (IDO)
|
|
|
(S)-Indoximod-d3 is the deuterium labeled (S)-Indoximod. (S)-Indoximod (1-Methyl-L-tryptophan) is an inhibitor of indoleamine 2,3-dioxygenase (IDO). (S)-Indoximod can be used for the research of cancer[1][2][3].
|
-
- HY-148818
-
|
S-Me-DM4
|
ADC Cytotoxin
|
Others
|
|
S-Me-DM4 is a metabolite of DM4 S-methylated by intracellular enzyme. DM4 (HY-100503) is a microtubule-depolymerizing maytansinoid with strong cytotoxicity. DM4 can be used as an ADC Cytotoxin molecule.
|
-
- HY-111652
-
|
S-Gboxin
|
Others
|
Cancer
|
|
S-Gboxin, a functional analogue of Gboxin, inhibits growth of mouse and human glioblastoma (GBM) with an IC50 of 470 nM. Antitumour activity.
|
-
- HY-145532
-
|
S-Allylmercaptocysteine
|
Apoptosis
NF-κB
Keap1-Nrf2
|
Cancer
Inflammation/Immunology
|
|
S-allylmercaptocysteine, an organic sulfur compound extracted from garlic, has anti-inflammatory and anti-oxidative effects for various pulmonary diseases. S-allylmercaptocysteine achieves its anti-cancer effect through a variety of pathways such as inducing the apoptosis of cancer cells through the TGF-β signaling pathway, or reducing the NF-κB activity and up-regulating Nrf2 to achieve the effects of anti-inflammation and anti-oxidation.
|
-
- HY-130189
-
-
- HY-W017413
-
-
- HY-100742B
-
-
- HY-111664A
-
-
- HY-U00366
-
-
- HY-18099A
-
|
S1RA hydrochloride
E-52862 hydrochloride
|
Sigma Receptor
5-HT Receptor
|
Neurological Disease
|
|
S1RA (E-52862) hydrochloride is an orally active and selective sigma-1 receptor (σ1R) antagonist with a Ki value of 17 nM. S1RA hydrochloride shows good selectivity against σ2R (Ki >1000 nM). S1RA hydrochloride is a human 5-HT2B receptor antagonist with an IC50 value of 4.7 μM. S1RA hydrochloride inhibits neuropathic pain and activity-induced spinal sensitization.
|
-
- HY-13238A
-
|
Dolutegravir sodium
S/GSK1349572 sodium
|
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM).
|
-
- HY-144881
-
-
- HY-W050031
-
|
(S)-3-Hydroxybutanoic acid
(S)-β-Hydroxybutanoic acid; L-(+)-3-Hydroxybutyric acid; L-β-Hydroxybutyric acid
|
Endogenous Metabolite
|
Others
|
|
(S)-3-Hydroxybutanoic acid is a normal human metabolite, that has been found elevated in geriatric patients remitting from depression. In humans, 3-Hydroxybutyric acid is synthesized in the liver from acetyl-CoA, and can be used as an energy source by the brain when blood glucose is low.
|
-
- HY-124300A
-
-
- HY-145900
-
|
S100A2-p53-IN-1
|
MDM-2/p53
|
Cancer
|
|
S100A2-p53-IN-1 (compound 51) is a S100A2-p53 interactions inhibitor. S100A2 is a Ca 2+ binding protein with implications in cell signaling and is known to be upregulated in pancreatic cancer. S100A2-p53-IN-1 can inhibit the growth of the MiaPaCa-2 pancreatic cancer cell line (GI 50 of 1.2-3.4 μM).
|
-
- HY-W016798
-
-
- HY-W000795
-
-
- HY-W009693
-
-
- HY-W014663
-
-
- HY-W009911
-
-
- HY-W013305
-
-
- HY-W013864
-
-
- HY-W050494
-
-
- HY-W003499
-
-
- HY-W008261
-
-
- HY-W022471
-
-
- HY-136006
-
-
- HY-133487B
-
-
- HY-136006A
-
-
- HY-133487
-
-
- HY-130711
-
|
(S,R,S)-AHPC-C3-NH2
VH032-C3-NH2
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader.
|
-
- HY-15035
-
|
S-Diclofenac
ACS 15; ATB-337
|
COX
|
Inflammation/Immunology
|
|
S-Diclofenac is a hybrid molecule of an H2S donor and the NSAID diclofenac. S-Diclofenac spares the gastric mucosa of injury despite markedly suppressing prostaglandin synthesis.
|
-
- HY-100390
-
|
(S)-ML753286
|
BCRP
|
Cancer
|
|
(S)-ML753286 is a breast cancer resistance protein (BCRP) inhibitor with an IC50 of 0.6 μM on BCRP efflux transporter.
|
-
- HY-60264
-
-
- HY-148115
-
|
S1p receptor agonist 2
|
LPL Receptor
|
Inflammation/Immunology
|
|
S1p receptor agonist 2 (compound 1) is an agonist of S1P5 receptor, exhibits selectivity over the S1P1 and/or S1P3 receptors. S1p receptor agonist 2 can be used for endogenous SIP signaling system research, and alleviating or preventing CNS disorders research, such as neurodegenerative disorders.
|
-
- HY-148092
-
|
(S)-PM-43I
|
STAT
|
Cancer
Inflammation/Immunology
|
|
(S)-PM-43I is a potent STAT6 inhibitor and can reduce STAT6 phosphorylation level. (S)-PM-43I can be used in allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease and cancer research[1].
|
-
- HY-115688A
-
|
(S)-TXNIP-IN-1
|
Others
|
Others
|
|
(S)-TXNIP-IN-1 is the less active S-enantiomer of TXNIP-IN-1 (HY-115688). TXNIP-IN-1 is a TXNIP-TRX complex inhibitor which can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease
|
-
- HY-122376
-
|
S-Bioallethrin
D-Trans-Allethrin; Esbiol
|
Sodium Channel
|
Neurological Disease
|
|
S-Bioallethrin is a pyrethroid insecticide. S-Bioallethrin disrupts nerve function by modifying the gating kinetics of transitions between the conducting and nonconducting states of voltage-gated sodium channels.
|
-
- HY-W141791
-
-
- HY-13047
-
-
- HY-W014238
-
-
- HY-17368
-
|
Rivastigmine
S-Rivastigmine
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Rivastigmine (S-Rivastigmine) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.
|
-
- HY-P3433
-
|
Sarafotoxin S6b
|
Endothelin Receptor
|
Cardiovascular Disease
|
|
Sarafotoxin S6b is a vasoconstrictor peptide, and a non-selective endothelin receptor agonist. Sarafotoxin S6b can induce contraction in isolated human coronary arteries , the Ki values of Coronary artery, Saphenous vein and Coronary artery are 0.27, 0.55 and 19.5 nM, respectively.
|
-
- HY-W008467
-
-
- HY-W016552
-
-
- HY-115754
-
-
- HY-135233
-
-
- HY-P1112
-
-
- HY-152097
-
|
(S)-ZG197
|
Bacterial
|
Infection
|
|
(S)-ZG197 is a highly selective Staphylococcus aureus Caseinolytic protease P (SaClpP) activator with an EC50 of 1.4 μM.
|
-
- HY-15030
-
-
- HY-Z0478
-
|
(-)-Limonene
(S)-(-)-Limonene
|
Others
|
Cardiovascular Disease
|
|
(-)-Limonene ((S)-(-)-Limonene) is a monoterpene found in citrus plants like lemon, orange, and grape. (-)-Limonene can induce a mild bronchoconstrictive effect.
|
-
- HY-114398A
-
|
(S)-BAY-293
|
Others
|
Others
|
|
(S)-BAY-293 is a negative control of BAY 293. BAY 293 is a potent KRAS-SOS1 interaction inhibitor.
|
-
- HY-W087444A
-
-
- HY-W011102
-
|
S-Trityl-L-cysteine
NSC 83265; S-Tritylcysteine; 3-Tritylthio-L-alanine
|
Kinesin
Apoptosis
|
Cancer
|
|
S-Trityl-L-cysteine (NSC 83265) is a selective and allosteric kinesin Eg5 inhibitor with an IC50 of 1 μM for the inhibition of basal ATPase activity and 140 nM for the microtubule-activated ATPase activity. S-Trityl-L-cysteine has antitumor activities.
|
-
- HY-136183
-
-
- HY-129937
-
|
(S)-GNE-987
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
(S)-GNE-987 (compound 4), the GNE-987 (a chimeric BET degrader) hydroxy-proline epimer, abrogates binding to von Hippel-Lindau and does not degrade BRD4 protein. (S)-GNE-987 binds to the BRD4 BD1(IC50=4 nM) and BD2 (3.9 nM) bromodomains and can be used to design PROTAC-Antibody Conjugate (PAC).
|
-
- HY-W018628
-
-
- HY-W002410
-
-
- HY-W002519
-
-
- HY-W050023
-
-
- HY-I0109
-
-
- HY-136186
-
-
- HY-144126
-
|
S1P1 agonist 5
|
LPL Receptor
|
Inflammation/Immunology
|
|
S1P1 agonist 5 is a selective and orally active S1P1 agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS).
|
-
- HY-101265
-
|
S1p receptor agonist 1
|
LPL Receptor
|
Inflammation/Immunology
|
|
S1p receptor agonist 1 is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). S1p receptor agonist 1 has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). S1p receptor agonist 1 is extracted from patent WO2015039587A1, Compound 2.
|
-
- HY-34597
-
-
- HY-102029
-
-
- HY-B1352
-
|
L-Ornithine
(S)-2,5-Diaminopentanoic acid
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Ornithine ((S)-2,5-Diaminopentanoic acid) is a non-proteinogenic amino acid, is mainly used in urea cycle removing excess nitrogen in vivo. L-Ornithine shows nephroprotective.
|
-
- HY-144153S
-
-
- HY-106991A
-
|
Amustaline dihydrochloride
S-303 dihydrochloride
|
HIV
Bacterial
|
Infection
|
|
Amustaline (S-303) dihydrochloride, a nucleic acid-targeted alkylator, is an efficient pathogen inactivation agent for blood components containing red blood cells. Amustaline dihydrochloride has three components: an acridine anchor (an intercalator that targets nucleic acids non-covalently), an effector (a bis-alkylator group that reacts with nucleophiles), and a linker (a small flexible carbon chain containing a labile ester bond that hydrolyzes at neutral pH to yield non-reactive breakdown products).
|
-
- HY-W096147
-
-
- HY-15123
-
-
- HY-W014663S
-
-
- HY-N8942
-
-
- HY-130711A
-
|
(S,R,S)-AHPC-C3-NH2 TFA
VH032-C3-NH2 TFA
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-C3-NH2 TFA (VH032-C3-NH2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader.
|
-
- HY-110402
-
|
(S,R,S)-AHPC TFA
VH032-NH2 TFA; VHL ligand 1 TFA
|
Ligands for E3 Ligase
|
Cancer
|
|
(S,R,S)-AHPC (VH032-NH2) TFA is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC TFA can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC50 of 1.11 μM in Ba/F3 cells.
|
-
- HY-W012214
-
-
- HY-W006185
-
-
- HY-W008079
-
-
- HY-W011567
-
-
- HY-W004063
-
-
- HY-141845
-
-
- HY-18099
-
-
- HY-126126
-
-
- HY-141159A
-
-
- HY-13259C
-
|
(R)-MG-132
(S,R,S)-(-)-MG-132; Z-Leu-D-Leu-Leu-al
|
Proteasome
|
Cancer
|
|
(R)-MG-132 ((S,R,S)-(-)-MG-132) is the enantiomer of MG-132. (R)-MG-132 is a proteasome inhibitor with weaker cell cytotoxicity than MG-132. (R)-MG-132 stereoisomer is a more potent proteasome inhibitor than MG-132.
|
-
- HY-116514
-
-
- HY-108496
-
|
Sphingosine-1-phosphate
S1P
|
Endogenous Metabolite
LPL Receptor
|
Endocrinology
|
|
Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca 2+ as an extracellular ligand for G protein-coupled receptors. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids.
|
-
- HY-13238
-
|
Dolutegravir
S/GSK1349572
|
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM).
|
-
- HY-130654
-
|
(S,R,S)-AHPC-C2-PEG4-N3
VH032-C2-PEG4-N3
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. (S,R,S)-AHPC-C2-PEG4-N3 can be used in the synthesis of vRucaparib-TP4 (HY-130647). vRucaparib-TP4 a highly potent PARP1 degrader with a half-maximal degrading concentration (DC50) of 82 nM.
|
-
- HY-W013579
-
|
(S)-(+)-Carvone
D-Carvone
|
Others
|
Others
|
|
(S)-(+)-Carvone (D Carvone) is a naturally occuring conmpound found in several food items and can be used in flavouring foods.
|
-
- HY-129356A
-
-
- HY-14744
-
|
Levamlodipine
(S)-Amlodipine; Levoamlodipine
|
Calcium Channel
|
Others
|
|
Levamlodipine ((S)-Amlodipine) is a powerful dihydropyridine calcium channel blocker, possessing vasodilation properties and used in the treatment of hypertension and angina.
|
-
- HY-N0455A
-
-
- HY-15146
-
|
NSC 74859
S3I-201
|
STAT
|
Cancer
|
|
NSC 74859 (S3I-201) is a selective Stat3 inhibitor with an IC50 of 86 μM.
|
-
- HY-W051093
-
-
- HY-W014742
-
-
- HY-W019684
-
-
- HY-W251393
-
-
- HY-W022405
-
-
- HY-129942
-
|
S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate
|
ADC Linker
|
Cancer
|
|
S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is a glutathione cleavable ADC linker used for the antibody-drug conjugates (ADCs) and refers to the Alkyl-Chain composition. S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is the linker portions of the molecules employed for mAb attachment purposes.
|
-
- HY-148198
-
-
- HY-115734
-
|
Phenylpyropene C
S14-95
|
Acyltransferase
|
Inflammation/Immunology
|
|
Phenylpyropene C (S14-95), a JAK/STAT pathway inhibitor, can inhibit IFN-γ mediated expression of the reporter gene (IC50=5.4~10.8 μM). Phenylpyropene C also is an inhibitor of acyl-CoA, with an IC50 of 16.0 μM.
|
-
- HY-139612A
-
|
(S)-JDQ-443
(S)-NVP-JDQ443
|
Ras
PERK
|
Cancer
|
|
(S)-JDQ-443 is an isomer of JDQ-443 (HY-139612). JDQ-443 is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). JDQ-443 shows antitumor activity.
|
-
- HY-P1112A
-
-
- HY-N0363A
-
|
(+)-Columbianetin acetate
(S)-Columbianetin acetate
|
Fungal
|
Infection
Inflammation/Immunology
|
|
(S)-Columbianetin acetate is an isomer of Columbianetin. Columbianetin is a phytoalexin associated with celery (Apium graveolens) resistance to pathogens during storage. Columbianetin exhibits excellent anti-fungal and anti-inflammatory activity.
|
-
- HY-W040416
-
-
- HY-W018050
-
-
- HY-W014259
-
-
- HY-111540B
-
|
(S)-IDO1-IN-5
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
(S)-IDO1-IN-5 (Example 1B) is an active S-isomer of IDO1-IN-5. (S)-IDO1-IN-5 binds to IDOL with an IC50 value less than 1.5 µΜ. IDO1-IN-5 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.
|
-
- HY-143423A
-
|
(S)-MALT1-IN-5
|
MALT1
|
Cancer
Inflammation/Immunology
|
|
(S)-MALT1-IN-5 is a potent inhibitor of MALT1 protease. (S)-MALT1-IN-5 inhibits the activity of MALT1 is expected to be able to correct the enhancement of MALT1 activity due to abnormality of T cell receptor signal or B cell receptor signal, and cancer or inflammatory disease caused by MALT1 activity is expected. (S)-MALT1-IN-5 has the potential for the research of MALT1-related diseases (extracted from patent WO2020111087A1, compound 1).
|
-
- HY-136008
-
-
- HY-133487A
-
-
- HY-136006B
-
-
- HY-130711B
-
-
- HY-W017770
-
-
- HY-Y0017S
-
-
- HY-131254
-
-
- HY-143865
-
|
S1PR1 agonist 2
|
LPL Receptor
|
Inflammation/Immunology
|
|
S1PR1 agonist 2 is a potent agonist of S1PR1. Sphingosine-1-phosphate (S1P) is a cell membrane-derived lysophospholipid signalling molecule that exerts its physiological functions mainly by stimulating some members of the G protein-coupled receptor family. S1PR1 agonist 2 has the potential for the research of autoimmune diseases (extracted from patent WO2021175225A1, compound 1).
|
-
- HY-143864
-
|
S1PR1 agonist 1
|
LPL Receptor
|
Inflammation/Immunology
|
|
S1PR1 agonist 1 is a potent agonist of S1PR1. Sphingosine-1-phosphate (S1P) is a cell membrane-derived lysophospholipid signalling molecule that exerts its physiological functions mainly by stimulating some members of the G protein-coupled receptor family. S1PR1 agonist 1 has the potential for the research of autoimmune diseases (extracted from patent WO2021175223A1, compound 22).
|
-
- HY-114269
-
-
- HY-D1450
-
|
IR-1048
S01448
|
Fluorescent Dye
|
Cancer
|
|
IR-1048 (S01448) is a dye and also is a photothermal agent. IR-1048 can be used for the research of tumor diagnosis.
|
-
- HY-79130
-
|
Fmoc-(S)-phenylglycine
Benzeneacetic acid, α-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, (S)-; (S)-2-[[[(9H-Fluoren-9-yl)methoxy]carbonyl]amino]phenylethanoic acid; (S)-N-Fmoc-α-phenylglycine; N-9-Fluorenylmethoxycarbonyl-L-phenylglycine
|
Amino Acid Derivatives
|
Others
|
|
Fmoc-(S)-phenylglycine is a Glycine (HY-Y0966) derivative.
|
-
- HY-W007679
-
-
- HY-W011537
-
-
- HY-W010913
-
-
- HY-W007620
-
-
- HY-W019683
-
-
- HY-W013292
-
-
- HY-W012133
-
-
- HY-W009110
-
-
- HY-W017256
-
-
- HY-128888B
-
|
(S,R)-GSK321
|
Isocitrate Dehydrogenase (IDH)
|
Cancer
|
|
(S,R)-WT IDH1 Inhibitor 2 (GSK321) is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. (S,R)-WT IDH1 Inhibitor 2 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. (S,R)-WT IDH1 Inhibitor 2 can be used for research of acute myeloid leukemia (AML) and other cancers.
|
-
- HY-17038A
-
|
Agomelatine hydrochloride
S-20098 hydrochloride
|
Melatonin Receptor
5-HT Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine hydrochloride is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively.
|
-
- HY-17038
-
|
Agomelatine
S-20098
|
Melatonin Receptor
5-HT Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively.
|
-
- HY-W013573
-
-
- HY-118557
-
|
Iferanserin
S-MPEC
|
5-HT Receptor
|
Inflammation/Immunology
|
|
Iferanserin (S-MPEC) is a selective 5-HT receptor (serotonin receptor) antagonist with an affinity for 5-HT2A receptor. Iferanserin has the potential for internal hemorrhoid disease treatment.
|
-
- HY-B0311A
-
|
Carbidopa monohydrate
(S)-(-)-Carbidopa monohydrate
|
Aryl Hydrocarbon Receptor
|
Cancer
Neurological Disease
|
|
Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth.
|
-
- HY-B0311
-
|
Carbidopa
(S)-(-)-Carbidopa
|
Aryl Hydrocarbon Receptor
|
Cancer
Neurological Disease
|
|
Carbidopa ((S)-(-)-Carbidopa), a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa inhibits pancreatic cancer cell and tumor growth.
|
-
- HY-136055
-
-
- HY-130816
-
|
(S,R,S)-AHPC-O-Ph-PEG1-NH2
VH032-O-Ph-PEG1-NH2
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-O-Ph-PEG1-NH2 (VH032-O-Ph-PEG1-NH2) is E3 ligase ligand-linker conjugate and incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-O-Ph-PEG1-NH2 is used in PROTAC EED degrader-1 (HY-130614). PROTAC EED degrader-1 is a PROTAC targeting EED with a pKD of 9.02.
|
-
- HY-B1059
-
-
- HY-136187
-
-
- HY-D0205
-
-
- HY-109025
-
|
Baloxavir marboxil
S-033188; RG 6152
|
Influenza Virus
|
Infection
|
|
Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A and B virus.
|
-
- HY-W011324
-
-
- HY-W005143
-
-
- HY-B0617S
-
-
- HY-B0330S1
-
|
(S)-Ofloxacin-d3
|
Bacterial
Antibiotic
|
Infection
|
|
(S)-Ofloxacin-d3 is the deuterium labeled Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
|
-
- HY-Y0703
-
-
- HY-Y1889
-
-
- HY-19627A
-
|
Naldemedine tosylate
S-297995 tosylate
|
Opioid Receptor
|
Metabolic Disease
Neurological Disease
|
|
Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine tosylate is predicted to bind to 3CL pro encoded by SARS-CoV2 genome.
|
-
- HY-19627
-
|
Naldemedine
S-297995
|
Opioid Receptor
|
Metabolic Disease
Neurological Disease
|
|
Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine is predicted to bind to 3CL pro encoded by SARS-CoV2 genome.
|
-
- HY-141342
-
-
- HY-138748
-
-
- HY-141340
-
-
- HY-141350
-
-
- HY-141347
-
-
- HY-141343
-
-
- HY-130209
-
-
- HY-133473
-
-
- HY-141341
-
-
- HY-141346
-
-
- HY-138758
-
-
- HY-138752
-
-
- HY-141178A
-
-
- HY-140859
-
-
- HY-141348
-
-
- HY-138755
-
-
- HY-N0650
-
-
- HY-140600
-
-
- HY-141344
-
-
- HY-133477
-
-
- HY-141345
-
-
- HY-W007136
-
-
- HY-143432A
-
|
(S)-Cdc7-IN-18
|
CDK
|
Cancer
|
|
(S)-Cdc7-IN-18 is a potent inhibitor of CDC7. Overexpression of huCdc7 promotes overactivation of MCM2, an important marker of tumor cells, and thus promotes aberrant proliferation of tumor cells. (S)-Cdc7-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2020239107A1, compound 1-1).
|
-
- HY-115831
-
|
SAR247799
S1P1 agonist 3
|
LPL Receptor
|
Cardiovascular Disease
|
|
SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist, with EC50s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome.
|
-
- HY-W012003
-
-
- HY-W014913
-
-
- HY-125846
-
|
(S,R,S)-AHPC-PEG1-OTs
VH032-PEG1-OTs; VHL Ligand-Linker Conjugates 2; E3 ligase Ligand-Linker Conjugates 51
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG1-OTs is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.
|
-
- HY-79271
-
-
- HY-103608
-
|
(S,R,S)-AHPC-(C3-PEG)2-C6-Cl
VHL Ligand-Linker Conjugates 11; E3 ligase Ligand-Linker Conjugates 11
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-(C3-PEG)2-C6-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-(C3-PEG)2-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
|
-
- HY-W004153
-
-
- HY-117213
-
-
- HY-17380
-
|
(S)-Timolol Maleate
L-714,465 Maleate; MK 950
|
Adrenergic Receptor
|
Neurological Disease
Cardiovascular Disease
|
|
(S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction.
|
-
- HY-N1467
-
|
(-)-α-Terpineol
(S)-α-Terpineol
|
Others
|
Others
|
|
(-)-α-Terpineol ((S)-α-Terpineol), a monoterpene compound, is one of compounds in Melaleuca alternifolia.
|
-
- HY-146656S
-
-
- HY-117286
-
|
(S)-JQ-35
TEN-010
|
Epigenetic Reader Domain
|
Cancer
|
|
(S)-JQ-35 (TEN-010) is an inhibitor of the Bromodomain and Extra-Terminal (BET) family bromodomain-containing proteins with potential antineoplastic activity.
|
-
- HY-B0753
-
-
- HY-W011049
-
-
- HY-W053503
-
-
- HY-W011223
-
-
- HY-79288
-
-
- HY-N1459AS
-
-
- HY-W007573
-
-
- HY-W063269
-
-
- HY-W022796
-
-
- HY-W042016
-
-
- HY-W009197
-
-
- HY-W011652
-
-
- HY-17503S2
-
-
- HY-105545
-
|
Dexetimide
(+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide
|
mAChR
|
Neurological Disease
|
|
Dexetimide ((+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide) is a piperidine anticholinergic and a high-affinity muscarinic receptor antagonist. Dexetimide can be used in studies of parkinson's disease.
|
-
- HY-131168
-
-
- HY-130638
-
-
- HY-114176
-
-
- HY-34519
-
-
- HY-141411A
-
-
- HY-103599
-
|
(S,R,S)-AHPC-PEG2-N3
VH032-PEG2-N3; VHL Ligand-Linker Conjugates 6; E3 ligase Ligand-Linker Conjugates 13
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology.
|
-
- HY-103604
-
|
(S,R,S)-AHPC-PEG4-NH2 hydrochloride
VH032-PEG4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 4 hydrochloride; E3 ligase Ligand-Linker Conjugates 7
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.
|
-
- HY-103601
-
|
(S,R,S)-AHPC-PEG4-N3
VH032-PEG4-N3; VHL Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 4
|
E3 Ligase Ligand-Linker Conjugates
|
Others
|
|
(S,R,S)-AHPC-PEG4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.
|
-
- HY-103600
-
|
(S,R,S)-AHPC-PEG1-N3
VH032-PEG1-N3; VHL Ligand-Linker Conjugates 9; E3 ligase Ligand-Linker Conjugates 3
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.
|
-
- HY-103598
-
|
(S,R,S)-AHPC-PEG3-N3
VH032-PEG3-N3; VHL Ligand-Linker Conjugates 8; E3 ligase Ligand-Linker Conjugates 12
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG3-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
|
-
- HY-103602
-
|
(S,R,S)-AHPC-PEG3-NH2 hydrochloride
VH032-PEG3-NH2 hydrochloride; VHL Ligand-Linker Conjugates 1 hydrochloride; E3 ligase Ligand-Linker Conjugates 5
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
|
-
- HY-B0161A
-
|
Duloxetine hydrochloride
(S)-Duloxetine hydrochloride; LY-248686 hydrochloride
|
Serotonin Transporter
|
Neurological Disease
|
|
Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).
|
-
- HY-33466
-
-
- HY-14926
-
|
Levonadifloxacin
(S)-(-)-Nadifloxacin; WCK 771
|
Antibiotic
Bacterial
|
Infection
|
|
Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes.
|
-
- HY-130271
-
|
(S,R,S)-AHPC-PEG5-COOH
VH032-PEG5-COOH; VHL Ligand-Linker Conjugates 16; E3 Ligase Ligand-Linker Conjugates 58
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG5-COOH (VH032-PEG5-COOH) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 5-unit PEG linker used in PROTAC technology.
|
-
- HY-141317
-
-
- HY-138752A
-
-
- HY-131345A
-
|
(S)-PI3Kα-IN-4
|
PI3K
|
Cancer
|
|
(S)-PI3Kα-IN-4 is a potent inhibitor of PI3Kα, with an IC50 of 2.3 nM. (S)-PI3Kα-IN-4 shows 38.3-, 4.25-, and 4.93-fold selectivity for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively. (S)-PI3Kα-IN-4 can be used for the research of cancer.
|
-
- HY-N1459A
-
-
- HY-B2246A
-
|
D-Carnitine hydrochloride
(S)-Carnitine hydrochloride
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Carnitine hydrochloride ((S)-Carnitine Hydrochloride) has been used to study sulfur factor transporter SLC22A4 and carnitine transporter SLC22A5 in ergot. D-Carnitine hydrochloride is also used to get palmitic acid into mitochondria.
|
-
- HY-W008437
-
-
- HY-W013207
-
-
- HY-103606
-
|
(S,R,S)-AHPC-PEG6-C4-Cl
VH032-PEG6-C4-Cl; VHL Ligand-Linker Conjugates 10; E3 ligase Ligand-Linker Conjugates 9
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG6-C4-Cl is a conjugate of ligands for E3 and 25-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-PEG6-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker. (S,R,S)-AHPC-PEG6-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
|
-
- HY-17021B
-
|
Esomeprazole potassium salt
(S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt
|
Proton Pump
Bacterial
|
Cancer
Endocrinology
Inflammation/Immunology
|
|
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.
|
-
- HY-17021
-
|
Esomeprazole
(S)-Omeprazole; (-)-Omeprazole
|
Proton Pump
Bacterial
|
Cancer
Endocrinology
Inflammation/Immunology
|
|
Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.
|
-
- HY-15977
-
|
(S)-P7C3-OMe
|
Others
|
Neurological Disease
|
|
(S)-P7C3-OMe, P7C3-A20 hydroxylated analog, is the (S)-enantiomer of P7C3-OMe. P7C3-OMe is a pro-neurogenic compound, can be used for the research of neuropsychiatric and/or neurodegenerative disease.
|
-
- HY-103602A
-
|
(S,R,S)-AHPC-PEG3-NH2
VH032-PEG3-NH2; VHL Ligand-Linker Conjugates 1; E3 ligase Ligand-Linker Conjugates 5 Free Base
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
|
-
- HY-103604A
-
|
(S,R,S)-AHPC-PEG4-NH2
VH032-PEG4-NH2; VHL Ligand-Linker Conjugates 4 ; E3 ligase Ligand-Linker Conjugates 7 Free Base
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.
|
-
- HY-W011280
-
-
- HY-W014303
-
-
- HY-79680
-
-
- HY-141349
-
-
- HY-N0455
-
|
L-Arginine
(S)-(+)-Arginine
|
NO Synthase
Endogenous Metabolite
|
Cardiovascular Disease
Cancer
|
|
L-Arginine ((S)-(+)-Arginine) is the substrate for the endothelial nitric oxide synthase (eNOS) to generate NO. L-Arginine is transported into vascular smooth muscle cells by the cationic amino acid transporter family of proteins where it is metabolized to nitric oxide (NO), polyamines, or L-proline.
|
-
- HY-103607
-
|
(S,R,S)-AHPC-PEG2-C4-Cl
VH032-PEG2-C4-Cl; VHL Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 10
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG2-C4-Cl (VH032-PEG2-C4-Cl) is a conjugate of ligands for E3 and 13-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-PEG2-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and an alkyl/ether-based linker. (S,R,S)-AHPC-PEG2-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
|
-
- HY-W011337
-
-
- HY-W048199
-
-
- HY-103603
-
|
(S,R,S)-AHPC-PEG2-NH2 hydrochloride
VH032-PEG2-NH2 hydrochloride; VHL Ligand-Linker Conjugates 3 hydrochloride; E3 ligase Ligand-Linker Conjugates 6
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG2-NH2 hydrochloride (VH032-PEG2-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.
|
-
- HY-19528
-
|
SAH
SAH (S-Adenosylhomocysteine)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM.
|
-
- HY-W440986S
-
-
- HY-N0394S2
-
-
- HY-W011203
-
-
- HY-41048
-
-
- HY-W040441
-
-
- HY-14744A
-
|
Levamlodipine besylate
(S)-Amlodipine besylate; Levoamlodipine besylate
|
Calcium Channel
|
Cardiovascular Disease
|
|
Levamlodipine besylate ((S)-Amlodipine besylate) is a powerful dihydropyridine calcium channel blocker, possessing vasodilation properties and used in the treatment of hypertension and angina.
|
-
- HY-44688
-
-
- HY-14258AS1
-
|
Escitalopram-d4 oxalate
(S)-Citalopram-d4 (oxalate); (S)-(+)-Citalopram-d4 (oxalate)
|
Serotonin Transporter
|
Neurological Disease
|
|
Escitalopram-d4 (oxalate) is deuterium labeled Escitalopram (oxalate). Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression[1][2].
|
-
- HY-20838B
-
-
- HY-B0471S2
-
-
- HY-121526
-
-
- HY-103603A
-
|
(S,R,S)-AHPC-PEG2-NH2
VH032-PEG2-NH2 ; VHL Ligand-Linker Conjugates 3 ; E3 ligase Ligand-Linker Conjugates 6 Free Base
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-PEG2-NH2 (VH032-PEG2-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.
|
-
- HY-116790
-
-
- HY-149034
-
|
Influenza A virus-IN-8
S5
|
Influenza Virus
|
Infection
|
|
Influenza A virus-IN-8 (S5) is a macrocyclic peptide with no cytotoxic. Influenza A virus-IN-8 is also a potent Influenza A Virus (IAV) inhibitor (with sufficient protease stability) with IC50s of 6.7 and 6.6 nM for H1 and H5 variants, respectively. Influenza A virus-IN-8 shows good affinitiescan to H1 variants, binds to a conserved region in the HA stem with a Kd of 1.0 nM.
|
-
- HY-B1050
-
|
Gemifloxacin mesylate
SB-265805S; LB-20304a
|
Bacterial
Antibiotic
DNA/RNA Synthesis
Topoisomerase
|
Infection
|
|
Gemifloxacin mesylate (SB-265805S; LB-20304a) is an orally active broad-spectrum quinolone antibacterial antibiotic. Gemifloxacin mesylate inhibits DNA synthesis by inhibiting DNA gyrase and Topoisomerase IV activities. Gemifloxacin mesylate has potent antibacterial activities against gram-positive bacteria in vitro efficacy study, particularly Streptococci and Staphylococci. Gemifloxacin mesylate has been used in the research of respiratory tract infections.
|
-
- HY-101671
-
-
- HY-17380S
-
|
(S)-Timolol-d9 maleate
L-714,465-d9 (maleate); MK 950-d9
|
Adrenergic Receptor
|
Neurological Disease
Cardiovascular Disease
|
|
(S)-Timolol-d9 (maleate) is deuterium labeled (S)-Timolol (Maleate). (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction[1][2][3].
|
-
- HY-77021
-
-
- HY-19717
-
|
DCVC
S-[(1E)-1,2-dichloroethenyl]--L-cysteine
|
TNF Receptor
|
Inflammation/Immunology
|
|
DCVC (S-[(1E)-1,2-dichloroethenyl]--L-cysteine) is a bioactive metabolite of trichloroethylene (TCE). DCVC inhibits pathogen-stimulated pro-inflammatory cytokines IL-1β, IL-8, and TNF-α release from tissue cultures.
|
-
- HY-B1532
-
|
Anabasine
(S)-Anabasine; (+)-Anabasine
|
nAChR
|
Neurological Disease
|
|
Anabasine ((S)-Anabasine) is an alkaloid that found as a minor component in tobacco (Nicotiana). Anabasine is a botanical pesticide nicotine, acts as a full agonist of nicotinic acetylcholine receptors (nAChRs). Anabasine induces depolarization of TE671 cells endogenously expressing human fetal muscle-type nAChRs (EC50=0.7 µM).
|
-
- HY-W014928
-
|
Anabasine hydrochloride
(S)-Anabasine hydrochloride; (+)-Anabasine hydrochloride
|
nAChR
|
Neurological Disease
|
|
Anabasine ((S)-Anabasine) hydrochloride is an alkaloid that found as a minor component in tobacco (Nicotiana). Anabasine is a botanical pesticide nicotine, acts as a full agonist of nicotinic acetylcholine receptors (nAChRs). Anabasine induces depolarization of TE671 cells endogenously expressing human fetal muscle-type nAChRs (EC50=0.7 µM).
|
-
- HY-17374
-
|
Benfotiamine
S-Benzoylthiamine O-monophosphate
|
Others
|
Neurological Disease
|
|
Benfotiamine (S-Benzoylthiamine O-monophosphate) is an analog of vitamin B1 with higher absorption and bioavailability than vitamin B1, and is commonly used as a food supplement for diabetic complications. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage.
|
-
- HY-W014304
-
-
- HY-N9022
-
-
- HY-17459
-
|
Clopidogrel hydrogen sulfate
(S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate
|
Cytochrome P450
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
|
Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor.
|
-
- HY-W018849
-
-
- HY-W010747
-
-
- HY-W013870
-
-
- HY-W010837
-
-
- HY-N2551
-
|
Vitamin U chloride
S-Methylmethionine sulfonium chloride
|
Others
|
Inflammation/Immunology
|
|
Vitamin U (S-Methylmethionine sulfonium) chloride is an orally active anti-ulcer agent with antioxidant activity. Vitamin U inhibits adipocyte differentiation. Vitamin U promotes skin wound healing.Vitamin U can be used in the research of gastrointestinal ulceration.
|
-
- HY-Y0028
-
-
- HY-17023
-
|
Esomeprazole sodium
(S)-Omeprazole sodium; (-)-Omeprazole sodium
|
Proton Pump
Bacterial
|
Endocrinology
Cancer
|
|
Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.
|
-
- HY-42938
-
-
- HY-W006152
-
-
- HY-145817A
-
|
RP-6306
(S)-RP-6306
|
Wee1
|
Cancer
|
|
RP-6306 ((S)-RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC50 of 14 nM. RP-6306 shows a high degree of selectivity over other kinases in cellular binding assays. RP-6306 shows anticancer effects.
|
-
- HY-123275A
-
|
H-D-Phe-Pip-Arg-pNA hydrochloride
S-2238 hydrochloride
|
Fluorescent Dye
|
Others
|
|
H-D-Phe-Pip-Arg-pNA (S-2238) hydrochloride, a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA hydrochloride is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA hydrochloride is sensitive, accurate, and easy to perform.
|
-
- HY-123275B
-
|
H-D-Phe-Pip-Arg-pNA acetate
S-2238 acetate
|
Fluorescent Dye
|
Others
|
|
H-D-Phe-Pip-Arg-pNA (S-2238) acetate, a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA acetate is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA acetate is sensitive, accurate, and easy to perform.
|
-
- HY-123275
-
|
H-D-Phe-Pip-Arg-pNA
S-2238
|
Fluorescent Dye
|
Others
|
|
H-D-Phe-Pip-Arg-pNA (S-2238), a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA is sensitive, accurate, and easy to perform.
|
-
- HY-123275C
-
|
H-D-Phe-Pip-Arg-pNA dihydrochloride
S-2238 dihydrochloride
|
Fluorescent Dye
|
Others
|
|
H-D-Phe-Pip-Arg-pNA (S-2238) dihydrochloride, a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA dihydrochloride is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA dihydrochloride is sensitive, accurate, and easy to perform.
|
-
- HY-103605
-
|
(S,R,S)-AHPC-C6-PEG3-C4-Cl
VH032-C6-PEG3-C4-Cl; VHL Ligand-Linker Conjugates 12; E3 ligase Ligand-Linker Conjugates 8
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
|
(S,R,S)-AHPC-C6-PEG3-C4-Cl (VH032-C6-PEG3-C4-Cl) is a conjugate of ligands for E3 and 20-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-C6-PEG3-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and an alkyl/ether-based linker. (S,R,S)-AHPC-C6-PEG3-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
|
-
- HY-137430
-
|
Aldumastat
GLPG1972; S201086
|
Others
|
Metabolic Disease
|
|
Aldumastat (GLPG1972; S201086) is a potent, seletive and orally active ADAMTS-5 (IC50=19 nM) inhibitor, and has 8-fold seletivity over ADAMTS-4 (IC50=156 nM). Aldumastat has anticatabolic activity and is used for osteoarthritis research.
|
-
- HY-77026
-
-
- HY-75947
-
-
- HY-B0653
-
|
Levobupivacaine
(S)-(-)-Bupivacaine
|
Sodium Channel
Ferroptosis
|
Cancer
Neurological Disease
|
|
Levobupivacaine ((S)-(-)-Bupivacaine) is a long-acting amide local anaesthetic. Levobupivacaine exerts anaesthetic and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.
|
-
- HY-W010984
-
-
- HY-W010958
-
-
- HY-79417
-
-
- HY-151866A
-
|
(S)-N3-HABA (DCHA)
|
ADC Linker
|
Others
|
|
(S)-N3-HABA (DCHA) is a click chemistry reagent. Click chemistry has great potential for use in binding between nucleic acids, lipids, proteins, and other molecules, and has been used in many research fields because of its beneficial characteristics, including high yield, high specificity, and simplicity.
|
-
- HY-76326S
-
-
- HY-W017069
-
-
- HY-145362
-
-
- HY-100560
-
|
Abscisic acid
(S)-(+)-Abscisic acid; ABA
|
Endogenous Metabolite
Proton Pump
|
Metabolic Disease
|
|
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H +-ATPase) and leads to the plasma membrane depolarization in a Ca 2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome.
|
-
- HY-120051
-
|
Afizagabar
S44819; Egis-13529
|
GABA Receptor
|
Neurological Disease
|
|
Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the α5-GABAAR, with an IC50 of 585 nM for α5β2γ2 and a Ki of 66 nM for α5β3γ2. Afizagabar enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy.
|
-
- HY-W110126
-
-
- HY-108496S
-
|
Sphingosine-1-phosphate-d7
S1P-d7
|
Endogenous Metabolite
LPL Receptor
|
Endocrinology
|
|
Sphingosine-1-phosphate-d7 is the deuterium labeled Sphingosine-1-phosphate. Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca2+ as an extracellular ligand for G protein-coupled receptors[1]. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids[2].
|
-
- HY-17021C
-
|
Esomeprazole hemistrontium
(S)-Omeprazole hemistrontium; (-)-Omeprazole hemistrontium
|
Proton Pump
Bacterial
|
Cancer
Endocrinology
Inflammation/Immunology
|
|
Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research.
|
-
- HY-13238S1
-
|
Dolutegravir-d3
S/GSK1349572-d3
|
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir-d3 is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM)[1][2].
|
-
- HY-13238S2
-
|
Dolutegravir-d5
S/GSK1349572-d5
|
HIV Integrase
HIV
|
Infection
|
|
Dolutegravir-d5 is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM)[1][2].
|
-
- HY-W008667
-
-
- HY-Y0134
-
-
- HY-W011056
-
-
- HY-17021A
-
|
Esomeprazole magnesium salt
(S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt
|
Proton Pump
Bacterial
|
Cancer
Endocrinology
Inflammation/Immunology
|
|
Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research.
|
-
- HY-N0455B
-
|
L-Arginine (L-glutamate)
(S)-(+)-Arginine (L-glutamate)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Arginine L-glutamate ((S)-(+)-Arginine L-glutamate) is the nitrogen donor for synthesis of nitric oxide. L-Arginine L-glutamate can be used for upper gastrointestinal hypofunction or dysfunction like functional dyspepsia research.
|
-
- HY-B0653A
-
|
Levobupivacaine hydrochloride
(S)-(-)-Bupivacaine monohydrochloride
|
Sodium Channel
Ferroptosis
|
Neurological Disease
Cancer
|
|
Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local anaesthetic. Levobupivacaine hydrochloride exerts anaesthetic and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.
|
-
- HY-W040438
-
-
- HY-17038B
-
-
- HY-P99623
-
|
Flotetuzumab
MGD006; S80880
|
CD3
|
Cancer
|
|
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML).
|
-
- HY-N0224A
-
|
Goitrin
(S)-Goitrin; L-5-Vinyl-2-thiooxazolidone
|
Influenza Virus
|
Metabolic Disease
|
|
Goitrin ((S)-Goitrin), a product of glucosinolate-myrosinase reactions, is a potent inhibitor of thyroid peroxidase. Goitrin can inhibit iodine utilization by the thyroid. Goitrin also exhibits anti-influenza virus (H1N1) activity.
|
-
- HY-17397
-
|
Strontium Ranelate
Distrontium renelate; S12911
|
CaSR
|
Metabolic Disease
|
|
Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate can also activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling.
|
-
- HY-B1446
-
|
Esomeprazole magnesium
(S)-Omeprazole magnesium; (-)-Omeprazole magnesium
|
Proton Pump
|
Endocrinology
|
|
Esomeprazole magnesium ((S)-Omeprazole magnesium) is a potent and orally active H +, K +-ATPase inhibitor. Esomeprazole magnesium has the potential for upper intestinal disorders and gastroesophageal reflux disease research. Esomeprazole magnesium acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases.
|
-
- HY-W013108
-
-
- HY-W128037
-
-
- HY-17038S1
-
|
Agomelatine-d4
S-20098-d4
|
Melatonin Receptor
5-HT Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Agomelatine-d4 is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].
|
-
- HY-17038S2
-
|
Agomelatin-d3
S-20098-d3
|
Melatonin Receptor
5-HT Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Agomelatin-d3 is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].
|
-
- HY-W053705
-
-
- HY-16900
-
-
- HY-146659S
-
-
- HY-N0455AS2
-
|
L-Arginine-d7 hydrochloride
(S)-(+)-Arginine-d7 (hydrochloride)
|
NO Synthase
Endogenous Metabolite
|
Others
|
|
L-Arginine-d7 (hydrochloride) is the deuterium labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
|
-
- HY-N0455AS7
-
|
L-Arginine-13C hydrochloride
(S)-(+)-Arginine-13C (hydrochloride)
|
NO Synthase
Endogenous Metabolite
|
Others
|
|
L-Arginine- 13C (hydrochloride) is the 13C-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
|
-
- HY-32291
-
|
Methyl L-pyroglutamate
(S)-Methyl 5-oxopyrrolidine-2-carboxylate; L-Pyroglutamic acid methyl ester
|
Others
|
Others
|
|
Methyl L-pyroglutamate ((S)-Methyl 5-oxopyrrolidine-2-carboxylate;L-Pyroglutamic acid methyl ester) is isolated from P. oleracea and has anti-inflammatory activity.
|
-
- HY-P99318
-
|
Sonepcizumab
LT 1009; Anti-Human S1P Recombinant Antibody
|
LPL Receptor
|
Cancer
|
|
Sonepcizumab (LT 1009) is a fully humanized anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC).
|
-
- HY-101877
-
|
Statine
(3S,4S)-Statine; (S,S)-Statine
|
Others
|
Endocrinology
|
|
Statine is an unusual amino acid that occurs twice in the sequence of pepstatin, a protease inhibitor that is active against pepsin and other acid proteases.
|
-
- HY-B0311AS
-
|
Carbidopa-d3 monohydrate
(S)-(-)-Carbidopa-d3 (monohydrate)
|
Aryl Hydrocarbon Receptor
|
Cancer
Neurological Disease
|
|
Carbidopa-d3 (monohydrate) is the deuterium labeled Carbidopa monohydrate. Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth[1][2].
|
-
- HY-144354S
-
|
S-Benzyl-DL-cysteine-2,3,3-d3
|
Isotope-Labeled Compounds
|
Cancer
|
|
S-Benzyl-DL-cysteine-2,3,3-d3 is a deuterium labeled Benzylcysteine. Benzylcysteine is an ASCT2 inhibitor that binds to ASCT2 with an apparent Ki of 780 μM. Benzylcysteine inhibit ASCT2 function based on a competitive mechanism, indicating that Benzylcysteine binds to the substrate-binding site of ASCT2[1].
|
-
- HY-W008599
-
-
- HY-14744S
-
|
Levamlodipine-d4
(S)-Amlodipine-d4; Levoamlodipine-d4
|
Calcium Channel
|
Others
|
|
Levamlodipine-d4 is the deuterium labeled Levamlodipine. Levamlodipine ((S)-Amlodipine) is a powerful dihydropyridine calcium channel blocker, possessing vasodilation properties and used in the treatment of hypertension and angina[1].
|
-
- HY-19528S
-
|
SAH-d4
SAH (S-Adenosylhomocysteine)-d4
|
Endogenous Metabolite
|
Metabolic Disease
|
|
SAH-d4 is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM[2].
|
-
- HY-123024
-
|
Cefatrizine
BL-S-640; SK&F 60771
|
Apoptosis
Bacterial
Antibiotic
|
Cancer
Infection
|
|
Cefatrizine (BL-S-640) is an orally active and broad-spectrum cephalosporin antibiotic. Cefatrizine is also a eEF2K inhibitor, with anti-proliferative activity in human breast cancer cells, which could induce ER stress, leading to cell death. Cefatrizine can be used in studies of cancer and bacterial infection.
|
-
- HY-D0249
-
|
Sunset Yellow FCF
Orange Yellow S; Food Yellow 3; CI 15985
|
Fluorescent Dye
|
Others
|
|
Sunset Yellow FCF (Orange Yellow S) is a petroleum-derived orange azo dye with a pH dependent maximum absorption at about 480 nm at pH 1 and 443 nm at pH 13.
|
-
- HY-N0455AS3
-
|
L-Arginine-1-13C hydrochloride
(S)-(+)-Arginine-1-13C (hydrochloride)
|
NO Synthase
Endogenous Metabolite
|
Others
|
|
L-Arginine-1- 13C (hydrochloride) is the 13C-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
|
-
- HY-42487S
-
|
(S)-4-Ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione-d5
|
Isotope-Labeled Compounds
|
Others
|
|
(S)-4-Ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione-d5 is the deuterium labeled (S)-4-Ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione[1].
|
-
- HY-17022
-
|
Esomeprazole magnesium trihydrate
(S)-Omeprazole magnesium trihydrate; (-)-Omeprazole magnesium trihydrate
|
Proton Pump
|
Endocrinology
|
|
Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active H +, K +-ATPase inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research. Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases.
|
-
- HY-N0215S13
-
|
L-Phenylalanine-d1
(S)-2-Amino-3-phenylpropionic acid-d1
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine-d is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-N0650S11
-
|
L-Serine-d7
(-)-Serine-d7; (S)-Serine-d7
|
Endogenous Metabolite
|
|
|
L-Serine-d7 is the deuterium labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
|
-
- HY-N0650S8
-
|
L-Serine-d3
(-)-Serine-d3; (S)-Serine-d3
|
Endogenous Metabolite
|
Cancer
|
|
L-Serine-d3 is the deuterium labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
|
-
- HY-N0650S7
-
|
L-Serine-d2
(-)-Serine-d2; (S)-Serine-d2
|
Endogenous Metabolite
|
Cancer
|
|
L-Serine-d2 is the deuterium labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
|
-
- HY-N0215S
-
|
L-Phenylalanine-d7
(S)-2-Amino-3-phenylpropionic acid-d7
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine-d7 is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-N0215S3
-
|
L-Phenylalanine-d2
(S)-2-Amino-3-phenylpropionic acid-d2
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine-d2 is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-N0215S2
-
|
L-Phenylalanine-13C
(S)-2-Amino-3-phenylpropionic acid-13C
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine- 13C is the 13C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-N0215S1
-
|
L-Phenylalanine-d8
(S)-2-Amino-3-phenylpropionic acid-d8
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine-d8 is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-N0215S5
-
|
L-Phenylalanine-15N
(S)-2-Amino-3-phenylpropionic acid-15N
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine- 15N is the 15N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-N0650S10
-
|
L-Serine-15N
(-)-Serine-15N; (S)-Serine-15N
|
Endogenous Metabolite
|
Cancer
|
|
L-Serine- 15N is the 15N-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
|
-
- HY-N0650S1
-
|
L-Serine-13C
(-)-Serine-13C; (S)-Serine-13C
|
Endogenous Metabolite
|
Cancer
|
|
L-Serine- 13C is the 13C-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
|
-
- HY-N0455AS6
-
|
L-Arginine-13C6 hydrochloride
(S)-(+)-Arginine-13C6 (hydrochloride)
|
NO Synthase
Endogenous Metabolite
|
Others
|
|
L-Arginine- 13C6 (hydrochloride) is the 13C-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
|
-
- HY-N0455AS
-
|
L-Arginine-15N2 hydrochloride
(S)-(+)-Arginine-15N2 (hydrochloride)
|
NO Synthase
Endogenous Metabolite
|
Others
|
|
L-Arginine- 15N2 (hydrochloride) is the 15N-labeled L-Arginine (hydrochloride). L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
|
-
- HY-B0187A
-
|
Doripenem monohydrate
S 4661 monohydrate
|
Bacterial
Antibiotic
|
Infection
|
|
Doripenem monohydrate is a new member of the carbapenem class of beta-lactam antibiotics with broad-spectrum coverage of Gram-positive, Gram-negative and anaerobic pathogens.
|
-
- HY-B0187
-
|
Doripenem
S 4661
|
Bacterial
Antibiotic
|
Infection
|
|
Doripenem is a new member of the carbapenem class of beta-lactam antibiotics with broad-spectrum coverage of Gram-positive, Gram-negative and anaerobic pathogens.
|
-
- HY-N0455AS1
-
|
L-Arginine-15N4 hydrochloride
(S)-(+)-Arginine-15N4 (hydrochloride)
|
NO Synthase
Endogenous Metabolite
|
Others
|
|
L-Arginine- 15N4 (hydrochloride) is the 15N-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis[1].
|
-
- HY-N0215S7
-
|
L-Phenylalanine-3-13C
(S)-2-Amino-3-phenylpropionic acid-3-13C
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine-3- 13C is the 13C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-N2085
-
|
L-Perillaldehyde
(S)-(-)-Perillaldehyde; (S)-Perillaldehyde
|
Others
|
Neurological Disease
|
|
L-Perillaldehyde is a major component in the essential oil containing in Perillae Herba. Inhalation of L-Perillaldehyde shows antidepressant-like activity through the olfactory nervous function.
|
-
- HY-17438A
-
|
Cidofovir dihydrate
GS 0504 dihydrate; HPMPC dihydrate; (S)-HPMPC dihydrate
|
CMV
DNA/RNA Synthesis
Orthopoxvirus
Apoptosis
Endogenous Metabolite
|
Infection
Cancer
|
|
Cidofovir (GS 0504; HPMPC; (S)-HPMPC) dihydrate is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir dihydrate inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir dihydrate induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer. Cidofovir dihydrate also has anti-orthopoxvirus and anti-variola activities.
|
-
- HY-N0650S2
-
|
L-Serine-1-13C
(-)-Serine-1-13C; (S)-Serine-1-13C
|
Endogenous Metabolite
|
Cancer
|
|
L-Serine-1- 13C is the 13C-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
|
-
- HY-N0650S4
-
|
L-Serine-2-13C
(-)-Serine-2-13C; (S)-Serine-2-13C
|
Endogenous Metabolite
|
Cancer
|
|
L-Serine-2- 13C is the 13C-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
|
-
- HY-N0215S10
-
|
L-Phenylalanine-13C9
(S)-2-Amino-3-phenylpropionic acid-13C9
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine- 13C9 is the 13C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-N0215S8
-
|
L-Phenylalanine-13C6
(S)-2-Amino-3-phenylpropionic acid-13C6
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine- 13C6 is the 13C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-19528S1
-
|
SAH-13C5
SAH (S-Adenosylhomocysteine)-13C5
|
Endogenous Metabolite
|
Metabolic Disease
|
|
SAH- 13C5 is the 13C-labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM[2].
|
-
- HY-151190
-
|
cis-4-Br-2,5-F2-PCPA
S1024
|
Histone Demethylase
|
Cancer
|
|
cis-4-Br-2,5-F2-PCPA (S1024) is a selective inhibitor of lysine-specific demethylase 1 (LSD1), with a Ki value of 94 nM instead of 8.4 μM for LSD2. There is aberrant expression of LSD1 in cancer stem cells, cis-4-Br-2,5-F2-PCPA inhibits LSD1 cell proliferation and by increasing the level of dimethylated histone H3 at K4 (H3K4) in CCRF-CEM cells.
|
-
- HY-100606
-
|
l-Pindolol
(-)-Pindolol; (S)-(-)-Pindolol; S-Pindolol
|
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
|
|
l-Pindolol ((-)-pindolol) is a reversible, competitive and orally active 5-HT1A/1B antagonist. l-Pindolol is a partial β-adrenoceptor agonist. l-Pindolol can be used for the research of neurological disease.
|
-
- HY-N0455AS5
-
|
L-Arginine-1,2-13C2 hydrochloride
(S)-(+)-Arginine-1,2-13C2 (hydrochloride)
|
NO Synthase
Endogenous Metabolite
|
Others
|
|
L-Arginine-1,2- 13C2 (hydrochloride) is the 13C-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
|
-
- HY-N0215S14
-
|
L-Phenylalanine-15N,d8
(S)-2-Amino-3-phenylpropionic acid-15N,d8
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine- 15N,d8 is the deuterium and 15N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca2+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-N0650S
-
|
L-Serine-13C3
(-)-Serine-13C3; (S)-Serine-13C3
|
Endogenous Metabolite
|
Cancer
|
|
L-Serine- 13C3 is the 13C-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
|
-
- HY-N0068
-
-
- HY-10844
-
|
Pretomanid
PA-824; (S)-PA 824
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Pretomanid (PA-824) is an antibiotic used for the research of multi-drug-resistant tuberculosis affecting the lungs. Pretomanid exhibits a sub-micromolar MIC against M. tuberculosis (MTB). The MIC values of PA-824 against a panel of MTB pan-sensitive and Rifampin mono-resistant clinical isolates range from 0.015 to 0.25 µg/mL.
|
-
- HY-N0455AS9
-
|
L-Arginine-15N4,d7 hydrochloride
(S)-(+)-Arginine-15N4,d7 (hydrochloride)
|
NO Synthase
Endogenous Metabolite
|
Others
|
|
L-Arginine- 15N4,d7 (hydrochloride) is the deuterium and 15N-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
|
-
- HY-10259
-
-
- HY-13441
-
-
- HY-16763
-
-
- HY-N6770
-
-
- HY-16991
-
-
- HY-N0363
-
|
(+)-Columbianetin
(S)-Columbianetin
|
Fungal
|
Infection
Inflammation/Immunology
|
|
(+)-Columbianetin is an isomer of Columbianetin. Columbianetin is a phytoalexin associated with celery (Apium graveolens) resistance to pathogens during storage. Columbianetin exhibits excellent anti-fungal and anti-inflammatory activity.
|
-
- HY-B2031
-
-
- HY-N0235
-
-
- HY-19883
-
-
- HY-B1062
-
-
- HY-N1081A
-
|
Viteralone
(S)-Viteralone
|
Others
|
Cancer
|
|
Viteralone (compound 5) is a natural product that can be isolated from Vitex negundo. Viteralone is cytotoxic to HL-60 cancer cells.
|
-
- HY-W067716
-
-
- HY-121166
-
|
Levobetaxolol
(S)-Betaxolol
|
Adrenergic Receptor
|
Others
|
|
Levobetaxolol is a potent and high affinity β-adrenergic antagonist with IC50 values of 33.2, 2970, 709 nM for guinea pig atrial β1, tracheal β2 and rat colonic β3 receptors, respectively. Levobetaxolol reduces IOP (intraocular pressure). Levobetaxolol exhibits a micromolar affinity for L-type Ca21-channels. Levobetaxolol decreases the effects of ischaemia/reperfusion injury in rats. Levobetaxolol has the potential for the research of glaucoma.
|
-
- HY-N0215S11
-
|
L-Phenylalanine-13C9,15N
(S)-2-Amino-3-phenylpropionic acid-13C9,15N
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine- 13C9, 15N is the 13C- and 15N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-N0650S9
-
|
L-Serine-15N,d3
(-)-Serine-15N,d3; (S)-Serine-15N,d3
|
Endogenous Metabolite
|
Cancer
|
|
L-Serine- 15N,d3 is the deuterium and 15N-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
|
-
- HY-137346
-
|
DD-03-156
(S,R,S)-AHPC-Me-PEG2-dabrafenib
|
CDK
LIM Kinase (LIMK)
|
Cancer
|
|
DD-03-156 is a potent and selective degrader of CDK17 and LIMK2. The selectivity and potency of DD-03-156 is exquisite and makes an advanced starting point for the development of a chemical probe for the degradation of CDK17.
|
-
- HY-Y0168
-
-
- HY-106423
-
|
Mivobulin
NSC 613862; (S)-(-)-NSC 613862
|
Microtubule/Tubulin
|
Cancer
|
|
Mivobulin (NSC 613862) is a tubulin inhibitor, binds to tubulin in the region that overlaps the colchicine site, and inhibits tubulin polymerization. Mivobulin (NSC 613862) promotes the formation of abnormal polymers and a GTPase activity in the tubulin dimer. Anti-cancer activity.
|
-
- HY-N0455AS8
-
|
L-Arginine-13C6,15N4 hydrochloride
(S)-(+)-Arginine-13C6,15N4 (hydrochloride)
|
NO Synthase
Endogenous Metabolite
|
Others
|
|
L-Arginine- 13C6, 15N4 (hydrochloride) is the 13C- and 15N-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
|
-
- HY-N0650S6
-
|
L-Serine1-13C,15N
(-)-Serine-13C,15N; (S)-Serine-13C,15N
|
Endogenous Metabolite
|
Cancer
|
|
L-Serine1- 13C, 15N is the 13C- and 15N-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
|
-
- HY-N0927
-
|
(-)-Isocorypalmine
Tetrahydrocolumbamine; (S)-Tetrahydrocolumbamine
|
Dopamine Receptor
|
Others
|
|
(-)-Isocorypalmine (Tetrahydrocolumbamine), isolated from the crude base fraction of Corydalis chaerophylla, is a dopamine receptor ligand. Recombinant CYP719A21 displays strict substrate specificity and high affinity (Km=4.63 ± 0.71 μM) for (-)-Isocorypalmine.
|
-
- HY-17034A
-
|
Dexmedetomidine hydrochloride
(+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride
|
Adrenergic Receptor
|
Neurological Disease
Endocrinology
Cancer
|
|
Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects.
|
-
- HY-109025A
-
|
Baloxavir
Baloxavir acid; S-033447
|
Influenza Virus
|
Infection
|
|
Baloxavir (Baloxavir acid), derived from the prodrug Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity.
|
-
- HY-A0191
-
-
- HY-12719
-
|
Dexmedetomidine
(+)-Medetomidine; (S)-Medetomidine
|
Adrenergic Receptor
|
Neurological Disease
|
|
Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects.
|
-
- HY-15677
-
-
- HY-N0215S9
-
|
L-Phenylalanine-13C9,15N,d8
(S)-2-Amino-3-phenylpropionic acid-13C9,15N,d8
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine- 13C9, 15N,d8 is the deuterium, 13C-, and 15-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-B1895
-
-
- HY-B0161
-
-
- HY-109046
-
-
- HY-W015879
-
|
2-Heptanol
s-Heptyl alcohol
|
Bacterial
|
Inflammation/Immunology
|
|
2-Heptanol is one of chemical constituents identified in the essential oil of rhizome of Curcuma angustifolia and Curcuma zedoaria. Rhizome essential oil exhibited good antimicrobial and antioxidant activity.
|
-
- HY-U00214
-
|
Ibafloxacine
R835; S25930
|
Bacterial
|
Infection
|
|
Ibafloxacine (R835) is a fluoroquinolone antibiotic agent that is developed exclusively for veterinary use.
|
-
- HY-15229
-
|
Guadecitabine sodium
SGI-110 sodium; S-110 sodium
|
DNA Methyltransferase
|
Cancer
|
|
Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
|
-
- HY-13740
-
-
- HY-18715
-
|
Ornidazole (Levo-)
(S)-Ornidazole; Levornidazole
|
Bacterial
Parasite
|
Infection
|
|
Ornidazole Levo- is the levo-isomer of Ornidazole. Ornidazole is a 5-nitroimidazole derivative with antiprotozoal and antibacterial properties against anaerobic bacteria. Ornidazole Levo- is the less active isomer.
|
-
- HY-B0304
-
-
- HY-D0205A
-
-
- HY-16560
-
-
- HY-Y0479
-
-
- HY-N0650S5
-
|
L-Serine-13C3,15N
(-)-Serine-13C3,15N; (S)-Serine-13C3,15N
|
Endogenous Metabolite
|
Cancer
|
|
L-Serine- 13C3, 15N is the 13C- and 15N-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
|
-
- HY-N0455AS4
-
|
L-Arginine-13C6,15N4,d7 hydrochloride
(S)-(+)-Arginine-13C6,15N4,d7 (hydrochloride)
|
NO Synthase
Endogenous Metabolite
|
Others
|
|
L-Arginine- 13C6, 15N4,d7 (hydrochloride) is the deuterium, 13C-, and 15-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
|
-
- HY-B1178
-
|
Cotinine
(-)-Cotinine; (S)-Cotinine; NIH-10498
|
Endogenous Metabolite
|
Cancer
|
|
Cotinine ((-)-Cotinine), an alkaloid in tobacco and a major metabolite of nicotine, is used as a biological indicator to measure the composition of tobacco smoke
|
-
- HY-14943
-
|
Darinaparsin
ZIO-101; S-Dimethylarsino-glutathione
|
Apoptosis
|
Cancer
|
|
Darinaparsin (ZIO-101), an organic arsenical, is a mitochondrial-targeted agent. Darinaparsin induces apoptosis in ancer cells, and has anticancer effects.
|
-
- HY-14754
-
|
Salirasib
S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS
|
Ras
Autophagy
|
Cancer
|
|
Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.
|
-
- HY-15592A
-
|
Cabotegravir sodium
GSK-1265744 sodium; S/GSK1265744 sodium
|
HIV
HIV Integrase
|
Infection
|
|
Cabotegravir (GSK-1265744) sodium is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral drugs (ARVs). Cabotegravir sodium can be used to research AIDS.
|
-
- HY-B0682A
-
|
Mitiglinide calcium hydrate
KAD-1229; S-21403
|
Potassium Channel
|
Metabolic Disease
|
|
Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes.
|
-
- HY-W013886
-
|
Captopril EP Impurity J
S-Acetylcaptopril
|
Drug Metabolite
|
Others
|
|
Captopril EP Impurity J is an impurity of Captopril. Captopril (SQ-14534), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM).
|
-
- HY-15677A
-
-
- HY-113039
-
-
- HY-B0381B
-
-
- HY-15592
-
|
Cabotegravir
GSK-1265744; S/GSK1265744
|
HIV
HIV Integrase
|
Infection
|
|
Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral drugs (ARVs). Cabotegravir can be used to research AIDS.
|
-
- HY-101794
-
-
- HY-106583
-
|
Piroxicam cinnamate
Cinnoxicam; SPA-S-510; Sinartol
|
COX
|
Inflammation/Immunology
|
|
Piroxicam cinnamate (Cinnoxicam) is a cyclooxygenase (COX) inhibitor, with anti-inflammatory activity. Piroxicam cinnamate is stable under gastric conditions, can be used for inflammatory-degenerative osteoarticular diseases, rheumatic disorders, and varicocele (VC) associated oligoasthenospermia research.
|
-
- HY-14615
-
|
[6]-Gingerol
(S)-(+)-[6]Gingerol; 6-Gingerol
|
AMPK
Apoptosis
|
Cancer
|
|
[6]-Gingerol is an active compound isolated from Ginger (Zingiber officinale), exhibits a variety of biological activities including anticancer, anti-inflammation, and anti-oxidation.
|
-
- HY-136684
-
-
- HY-N0650S3
-
|
L-Serine-13C3,15N,d3
(-)-Serine-13C3,15N,d3; (S)-Serine-13C3,15N,d3
|
Endogenous Metabolite
|
Cancer
|
|
L-Serine- 13C3, 15N,d3 is the deuterium, 13C-, and 15-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
|
-
- HY-12355
-
|
Siponimod
BAF-312
|
LPL Receptor
|
Inflammation/Immunology
Neurological Disease
|
|
Siponimod (BAF-312) is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P1 and S1P5 over S1P2, S1P3, and S1P4, with EC50s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research -.
|
-
- HY-12355A
-
|
Siponimod hemifumarate
BAF-312 hemifumarate
|
LPL Receptor
|
Inflammation/Immunology
Neurological Disease
|
|
Siponimod (BAF-312) hemifumarate is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC50s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively). Siponimod hemifumarate can be used for multiple sclerosis (MS) research.
|
-
- HY-103019
-
|
Enitociclib
(+)-Enitociclib; (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib
|
CDK
|
Cancer
|
|
Enitociclib ((+)-Enitociclib) is an enanthiomer of BAY-1251152 with rotation (+). Enitociclib is a potent and selective CDK9 inhibitor with an IC50 of 3 nM. Enitociclib has anti-tumour activity.
|
-
- HY-13740G
-
|
Resiquimod (GMP)
R848 (GMP); S28463 (GMP)
|
Toll-like Receptor (TLR)
|
Cancer
Inflammation/Immunology
|
|
Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages.
|
-
- HY-D0845
-
-
- HY-B0130A
-
-
- HY-17398
-
|
Mitiglinide calcium
KAD-1229 anhydrous; S21403 anhydrous
|
Potassium Channel
|
Metabolic Disease
|
|
Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes.
|
-
- HY-W015114
-
-
- HY-17438
-
|
Cidofovir
GS 0504; HPMPC; (S)-HPMPC
|
CMV
Apoptosis
DNA/RNA Synthesis
Orthopoxvirus
Endogenous Metabolite
|
Infection
Cancer
|
|
Cidofovir (GS 0504) is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase. Cidofovir induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer. Cidofovir also has anti-orthopoxvirus and anti-variola activities.
|
-
- HY-107235
-
|
Saponin CP6
Clematoside S; Prosapogenin CP6
|
Others
|
Others
|
|
Saponin CP6 is a triterpenoid compound from the roots of Clematis grata.
|
-
- HY-41650
-
-
- HY-B0682
-
|
Mitiglinide
KAD-1229 free acid anhydrous; S21403 free acid anhydrous
|
Potassium Channel
|
Metabolic Disease
|
|
Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes.
|
-
- HY-W018865
-
-
- HY-19883S
-
-
- HY-17038S
-
-
- HY-16918
-
|
Heptamidine
SBi4211
|
Others
|
Cancer
Inflammation/Immunology
|
|
Heptamidine (SBi4211) is a potent Pentamidine-related inhibitor of the calcium-binding protein S100B (Kd=6.9 μM), selectively kills melanoma cells with S100B over those without S100B. Heptamidine is a useful tool for the investigation of Myotonic dystrophy (DM).
|
-
- HY-16918A
-
|
Heptamidine dimethanesulfonate
SBi4211 dimethanesulfonate
|
Others
|
Cancer
Inflammation/Immunology
|
|
Heptamidine dimethanesulfonate (SBi4211 dimethanesulfonate) is a potent Pentamidine-related inhibitor of the calcium-binding protein S100B (Kd=6.9 μM), selectively kills melanoma cells with S100B over those without S100B. Heptamidine is a useful tool for the investigation of Myotonic dystrophy (DM).
|
-
- HY-N3945
-
|
Glaucine
O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396
|
Phosphodiesterase (PDE)
Calcium Channel
Adrenergic Receptor
Dopamine Receptor
Influenza Virus
|
Infection
Inflammation/Immunology
|
|
Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum with antitussive, bronchodilation and anti-inflammatory properties. Glaucine is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor with Kis of 3.4 µM in human bronchus and polymorphonuclear leukocytes. Glaucine is also a non-selective α-adrenoceptor antagonist, a Ca 2+ entry blocker, and a weak dopamine D1 and D2 receptor antagonist. Glaucine has antioxidative and antiviral activities.
|
-
- HY-139866
-
-
- HY-101817
-
-
- HY-P3492
-
|
SARS-CoV-2-IN-34
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection.
|
-
- HY-100559
-
-
- HY-107660
-
-
- HY-111974
-
|
β-D-Glucopyranosyl abscisate
ABA-GE; (S)-cis,trans-Abscisic acid glucosyl ester
|
Others
|
Endocrinology
|
|
β-D-Glucopyranosyl abscisate (ABA-GE) is a hydrolyzable abscisic acid (ABA) conjugate that accumulates in the vacuole and presumably also in the endoplasmic reticulum. The deconjugation of β-D-Glucopyranosyl abscisate allows the rapid formation of free ABA in response to abiotic stress conditions such as dehydration and salt stress. β-D-Glucopyranosyl abscisate contributes to the maintenance of ABA homeostasis.
|
-
- HY-Y0479S
-
-
- HY-100633S
-
-
- HY-112665
-
|
Virginiamycin Complex
Streptogramin; Mikamycin; RP 7293
|
Antibiotic
Bacterial
|
Infection
|
|
Virginiamycin complex contains two streptogramin antibiotics, virginiamycin M1 and virginiamycin S1 produced by S. virginiae. As a complex, the two antibiotics act synergistically to irreversibly inhibit protein synthesis in bacteria.
|
-
- HY-151346
-
-
- HY-13746
-
|
Sardomozide
CGP 48664; SAM-486A
|
Others
|
Cancer
|
|
Sardomozide is an S-adenosylmethionine decarboxylase (SAMDC) inhibitor with an IC50 of 5 nM.
|
-
- HY-13746B
-
-
- HY-N7268
-
-
- HY-18012A
-
|
Spebrutinib besylate
AVL-292 benzenesulfonate; CC-292 besylate
|
Btk
|
Cancer
|
|
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a potent inhibitor of Btk kinase activity (IC50<0.5 nM, Kinact/Ki=7.69×10 4 M -1s -1s) in biochemical assays.
|
-
- HY-N6917
-
-
- HY-10532
-
|
SRT 1720
|
Sirtuin
Autophagy
|
Metabolic Disease
|
|
SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
|
-
- HY-W008947
-
|
SEW2871
|
LPL Receptor
ERK
Akt
|
Metabolic Disease
Inflammation/Immunology
Neurological Disease
|
|
SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC50 of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses.
|
-
- HY-N6916
-
-
- HY-N11139
-
-
- HY-111388A
-
|
SEL120-34A monohydrochloride
|
CDK
|
Cancer
|
|
SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3 nM for CDK8. SEL120-34A monohydrochloride weakly inhibits CDK9 (calculated IC50=1070 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 and STAT5 S726. Has anti-tumor activity.
|
-
- HY-N8151
-
-
- HY-B1895S
-
-
- HY-13740S
-
-
- HY-109025AS
-
|
Baloxavir-d5
Baloxavir acid-d5; S-033447-d5
|
Influenza Virus
|
Infection
|
|
Baloxavir-d5 is deuterium labeled Baloxavir. Baloxavir (Baloxavir acid), derived from the prodrug Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity[1][2].
|
-
- HY-10483
-
-
- HY-10482
-
-
- HY-N10495
-
|
Seconeolitsine
|
Antibiotic
Bacterial
Topoisomerase
|
Infection
|
|
Seconeolitsine, an antibiotic, and is an inhibitor of targeting topoisomerase I (TopA). Seconeolitsine also is a new antimicrobial agent that can inhibit S. pneumoniae growth. Seconeolitsine can inhibit TopA relaxation activity with an IC50 value of 17 μM. Seconeolitsine can be used for the research of S. pneumoniae infections resistant to other antibiotics.
|
-
- HY-151347
-
|
sRANKL-IN-3
|
RANKL/RANK
NF-κB
|
Inflammation/Immunology
|
|
sRANKL-IN-3 (Compound S3-15) is a potent, orally active and selective soluble RANKL (sRANKL) inhibitor with an IC50 of 0.19 μM. sRANKL-IN-3 can be targeted to inhibit soluble RANK-RANKL interactions. sRANKL-IN-3 can be used for the research of osteoporosis.
|
-
- HY-110128
-
-
- HY-15900
-
|
Voxtalisib
XL765; SAR245409
|
PI3K
mTOR
|
Cancer
|
|
Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC50s=39, 113, 9 and 43 nM for p110α, p110β, p110γ and p110δ, respectively), also inhibits DNA-PK (IC50=150 nM) and mTOR (IC50=157 nM). Voxtalisib (XL765) inhibits mTORC1 and mTORC2 with IC50s of 160 and 910 nM, respectively.
|
-
- HY-N5077
-
-
- HY-100560S
-
-
- HY-15592S1
-
-
- HY-139703
-
-
- HY-B0035S2
-
-
- HY-17593
-
|
Solithromycin
CEM-101; OP-1068
|
Bacterial
Antibiotic
|
Infection
|
|
Solithromycin (CEM-101) is an orally bioavailable, effective antimicrobial agent, with IC50s for inhibition of cell viability, protein synthesis, and growth rate are 7.5 ng/mL, 40 ng/mL, and 125 ng/mL for Streptococcus pneumonia, Staphylococcus aureus, and Haemophilus influenzae, respectively. Solithromycin binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis.
|
-
- HY-N5077B
-
-
- HY-N0450
-
|
Sinapine thiocyanate
|
P-glycoprotein
Cholinesterase (ChE)
|
Cancer
|
|
Sinapine thiocyanate is an alkaloid isolated from seeds of the cruciferous species. Sinapine thiocyanate exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine thiocyanate is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease.
|
-
- HY-12783
-
|
SCH 50911 hydrochloride
|
GABA Receptor
|
Neurological Disease
|
|
SCH 50911 hydrochloride, (+)-(S)-5,5-dimethylmorpholinyl-2-acetic acid, a selective, orally-active and competitive γ-Aminobutyric acid B GABA(B) receptor antagonist, binds to GABA(B) receptor with IC50 of 1.1 μM. SCH 50911 hydrochloride antagonizes GABA(B) autoreceptors, increasing the electrically-stimulated 3H overflow with an IC50 of 3 μM.
|
-
- HY-18307
-
|
SYN1143
|
c-Met/HGFR
|
Cancer
|
|
SYN1143 is a potent, selective and orally active dual inhibitor of c-Met/RON, with IC50s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on Lck, Tie2, Src, and BTK with IC50s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated.
|
-
- HY-Y0479AS
-
-
- HY-B0161AS
-
|
Duloxetine D3 hydrochloride
(S)-Duloxetine-d3 (hydrochloride); LY248686-d3 (hydrochloride)
|
Serotonin Transporter
|
Neurological Disease
|
|
Duloxetine-d3 (hydrochloride) is a deuterium labeled Duloxetine hydrochloride. Duloxetine hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD)[1][2].
|
-
- HY-19956
-
|
GI254023X
GI4023; SRI028594
|
MMP
|
Cancer
|
|
GI254023X is a potent MMP9 and ADAM10 inhibitor with IC50s of 2.5 and 5.3 nM, respectively.
|
-
- HY-12783A
-
|
SCH 50911
|
GABA Receptor
|
Neurological Disease
|
|
SCH 50911, (+)-(S)-5,5-dimethylmorpholinyl-2-acetic acid, a selective, orally-active and competitive γ-Aminobutyric acid B GABA(B) receptor antagonist, binds to GABA(B) receptor with IC50 of 1.1 μM. SCH 50911 antagonizes GABA(B) autoreceptors, increasing the electrically-stimulated 3H overflow with an IC50 of 3 μM.
|
-
- HY-B2226
-
-
- HY-16615
-
-
- HY-13287
-
-
- HY-109037
-
|
Mavacamten
MYK461; SAR439152
|
Myosin
|
Cardiovascular Disease
|
|
Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
|
-
- HY-16616
-
-
- HY-145029
-
-
- HY-15592AS
-
|
Cabotegravir-d3 sodium
GSK-1265744-d3 (sodium); S/GSK1265744-d3 (sodium)
|
HIV Integrase
|
Infection
|
|
Cabotegravir-d3 (sodium) is the deuterium labeled Cabotegravir sodium. Cabotegravir sodium is a highly potent HIV integrase inhibitor with an IC50 value of 2.5 nM for HIVADA. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltr
|
-
- HY-114800
-
|
Soporidine
RG4; SOP
|
Parasite
|
Others
|
|
Soporidine is an antagonist of germination of the parasitic plant Striga hermonthica. Soporidine specifically inhibits a S. hermonthica strigolactone receptor and inhibits the parasite's germination.
|
-
- HY-118980
-
-
- HY-101442
-
|
SR9238
|
LXR
|
Metabolic Disease
|
|
SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC50s of 214 nM and 43 nM for LXRα and LXRβ, respectively.
|
-
- HY-113284
-
|
Succinyladenosine
N6-Succinyl adenosine
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Succinyladenosine, the metabolic product of dephosphorylation of intracellular adenylosuccinic acid (S-AMP) by cytosolic 5-nucleotidase, is a biochemical marker of adenylosuccinase (ASL) deficiency.
|
-
- HY-N1312
-
|
Sinapaldehyde
|
Bacterial
|
Infection
|
|
Sinapaldehyde exhibits moderate antibacterial against Methicillin resistant S. aureus (MRSA) and E. coli with MIC values of 128 and 128 μg/mL.
|
-
- HY-104065
-
|
Pyrotinib
SHR-1258
|
EGFR
|
Cancer
|
|
Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively.
|
-
- HY-16988A
-
-
- HY-12003
-
-
- HY-108344
-
|
SNS-314
|
Aurora Kinase
|
Cancer
|
|
SNS-314 is a potent and selective aurora kinase inhibitor with IC50s of 9, 31, and 6 nM for aurora A, B and C, respectively.
|
-
- HY-112113
-
|
SLV-2436
SEL201-88; SEL-201
|
MNK
|
Cancer
|
|
SLV-2436 is a highly potent and ATP-competitive inhibitor of MNK1 and MNK2 with IC50s of 10.8 nM and 5.4 nM, respectively.
|
-
- HY-16988
-
|
SR9011
|
REV-ERB
|
Cancer
|
|
SR9011 is a REV-ERBα/β agonist with IC50s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively.
|
-
- HY-12163
-
|
Entinostat
MS-275; SNDX-275
|
HDAC
Autophagy
Apoptosis
|
Cancer
|
|
Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively.
|
-
- HY-122470
-
|
Stampidine
|
Reverse Transcriptase
HIV
|
Infection
|
|
Stampidine is a nucleoside reverse transcriptase inhibitor (NRTI) with potent and broad-spectrum anti-HIV activity. Stampidine inhibits the laboratory HIV-1 strain HTLVIIIB (B-envelope subtype) and primary clinical isolates with IC50s of 1 nM and 2 nM, respectively. Stampidine also inhibits NRTI-resistant primary clinical isolates and NNRTI-resistant clinical isolates with IC50s of 8.7 nM and 11.2 nM, respectively.
|
-
- HY-110177
-
|
SP-100030
|
NF-κB
|
Inflammation/Immunology
|
|
SP-100030 is a potent NF-κB and activator protein-1 (AP-1) double inhibitor (IC50s=50 and 50 nM, respectively). SP-100030 inhibits IL-2, IL-8, and TNF-alpha production in Jurkat and other T cell lines. SP-100030 decreases murine collagen-induced arthritis (CIA).
|
-
- HY-103463
-
|
SA57
|
FAAH
MAGL
|
Neurological Disease
|
|
SA57 is a potent, selective FAAH inhibitor with IC50s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC50s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC50 of 850 nM), but not other brain serine hydrolases.
|
-
- HY-112234
-
|
L-Sepiapterin
Sepiapterin
|
Endogenous Metabolite
|
Cancer
|
|
L-Sepiapterin (Sepiapterin) is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 S6K-dependent VEGFR-2 expression.
|
-
- HY-Y0007
-
-
- HY-16560S
-
|
Camptothecin-d5
Campathecin-d5; (S)-(+)-Camptothecin-d5; CPT-d5
|
Topoisomerase
ADC Cytotoxin
MicroRNA
Influenza Virus
Apoptosis
Fungal
Antibiotic
|
Cancer
Infection
|
|
Camptothecin-d5 is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].
|
-
- HY-101977
-
|
Selitrectinib
LOXO-195
|
Trk Receptor
|
Cancer
|
|
Selitrectinib (LOXO-195) is a next-generation TRK kinase inhibitor, with IC50s of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively.
|
-
- HY-10011
-
-
- HY-132847
-
-
- HY-100895
-
|
SAR-20347
|
JAK
|
Cancer
|
|
SAR-20347 is an inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50s of 0.6, 23, 26 and 41 nM, respectively.
|
-
- HY-10201
-
|
Sorafenib
Bay 43-9006
|
Raf
VEGFR
FLT3
Autophagy
Apoptosis
Ferroptosis
|
Cancer
|
|
Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator.
|
-
- HY-135855
-
|
SARS-CoV-IN-1
|
SARS-CoV
Parasite
|
Infection
|
|
SARS-CoV-IN-1 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-1 shows anti-Coronavirus activity with an EC50 of 4.9 μM in Vero cells. SARS-CoV-IN-1 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 15.4 and 133.2 nM; and IC90s of 25.7 and 459.1 nM; respectively. Antimalarial and antiviral activities.
|
-
- HY-10201A
-
|
Sorafenib Tosylate
Bay 43-9006 Tosylate
|
Raf
VEGFR
FLT3
Autophagy
Ferroptosis
Apoptosis
|
Cancer
|
|
Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator.
|
-
- HY-104065B
-
|
Pyrotinib dimaleate
SHR-1258 dimaleate
|
EGFR
|
Cancer
|
|
Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively.
|
-
- HY-10158S
-
|
Bosutinib D8
SKI-606-d8
|
Src
Bcr-Abl
Autophagy
|
Cancer
|
|
Bosutinib-d8 is a deuterium labeled Bosutinib. Bosutinib is a dual Src/Abl inhibitor with IC50s of 1.2 nM and 1 nM, respectively[1][2].
|
-
- HY-116437
-
|
Selatinib
|
EGFR
|
Cancer
|
|
Selatinib is a reversible and orally active dual EGFR and ErbB2 inhibitor with IC50s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects.
|
-
- HY-W089835
-
-
- HY-116856
-
-
- HY-13050
-
|
Sapitinib
AZD-8931
|
EGFR
|
Cancer
|
|
Sapitinib (AZD-8931) is a reversible, ATP competitive EGFR inhibitor of with IC50s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.
|
-
- HY-10501
-
|
SU14813
|
PDGFR
VEGFR
c-Kit
|
Cancer
|
|
SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.
|
-
- HY-18629
-
|
SU9516
|
CDK
Autophagy
Apoptosis
|
Cancer
|
|
SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC50s of 40, 200 nM, respectively.
|
-
- HY-10501A
-
-
- HY-15307
-
|
Belumosudil
KD025; SLx-2119
|
ROCK
|
Inflammation/Immunology
|
|
Belumosudil (KD025) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 µM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties.
|
-
- HY-N2417
-
|
Stearyl glycyrrhetinate
|
Bacterial
|
Infection
|
|
Stearyl glycyrrhetinate, a major component in licorice extract, has a MIC against S. aureus strains of more than 256 mg/L. Stearyl glycyrrhetinate has antibacterial effects.
|
-
- HY-15307A
-
|
Belumosudil mesylate
KD025 mesylate; SLx-2119 mesylate
|
ROCK
|
Inflammation/Immunology
|
|
Belumosudil mesylate (KD025 mesylate) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 µM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties.
|
-
- HY-100011
-
|
SR-3029
|
Casein Kinase
|
Cancer
|
|
SR-3029 is a potent and ATP competitive CK1δ and CK1ε inhibitor, with IC50s of 44 nM and 260 nM, respectively, and Kis of 97 nM for both kinases.
|
-
- HY-P99317
-
|
Solanezumab
Immunoglobulin G1, anti-(human β-amyloid) (human-mouse monoclonAnti-Human Abeta Recombinant Antibody
|
Amyloid-β
|
Neurological Disease
|
|
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease.
|
-
- HY-112066
-
|
SHIN1
RZ-2994
|
Others
|
Cancer
|
|
SHIN1 (RZ-2994) is a human serine hydroxymethyltransferse 1 and 2 (SHMT1/2) inhibitor with IC50s of 5 and 13 nM, respectively, in an in vitro assay.
|
-
- HY-B1899A
-
-
- HY-100349
-
|
SU4312
|
PDGFR
VEGFR
|
Cancer
|
|
SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC50s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC50s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively.
|
-
- HY-144269
-
|
SHR902275
|
Raf
|
Cancer
|
|
SHR902275 is a potent, selective, and orally active RAF inhibitor targeting RAS mutant cancers. SHR902275 has IC50s of 1.6 nM, 10 nM, and 5.7 nM for cRAF, bRAF wt, and bRAF V600E, respectively. SHR902275 shows cell growth inhibition with GI50s of 1.5 and 0.17 nM, 0.4 nM and 0.32 nM for H358, A375, Calu6, and SK-MEL2 cells respectively.
|
-
- HY-126319
-
|
SU5204
|
VEGFR
EGFR
|
Cancer
|
|
SU5204, a tyrosine kinase inhibitor, has IC50s of 4 and 51.5 μM for FLK-1 (VEGFR-2) and HER2, respectively.
|
-
- HY-12990
-
-
- HY-148799
-
|
Sevasemten
|
Myosin
|
Others
|
|
Sevasemten is an allosteric inhibitor of skeletal muscle myosin. Sevasemten exhibits selectively myosin inhibition with IC50s of ≤10 μM (skeletal), >100 μM (cardiac), respectively.
|
-
- HY-10492
-
|
Dinaciclib
SCH 727965
|
CDK
Apoptosis
|
Cancer
|
|
Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively.
|
-
- HY-131942
-
-
- HY-10201S
-
-
- HY-10201S1
-
-
- HY-112807
-
|
SGLT inhibitor-1
|
SGLT
|
Metabolic Disease
|
|
SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC50s of 43 nM and 9 nM, respectively.
|
-
- HY-108518
-
-
- HY-103097
-
|
ST271
|
Phospholipase
|
Others
|
|
ST271 is a potent inhibitor of protein tyrosine kinase (PTK), inhibits phospholipase D activation stimulated by fMet-Leu-Phe and PAF, with IC50s of 6.7 and 9 μM, respectively.
|
-
- HY-108907
-
|
SR-1277
|
Casein Kinase
|
Cancer
|
|
SR-1277 is a potent, selective and ATP competitive CK1δ/ε inhibitor, with IC50s of 49 nM and 260 nM, respectively. SR-1277 also inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9/cyclin K, with IC50s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively. SR-1277 can be used for the research of cancer.
|
-
- HY-10256A
-
|
Adezmapimod hydrochloride
SB 203580 hydrochloride; RWJ 64809 hydrochloride
|
p38 MAPK
Autophagy
Mitophagy
|
Inflammation/Immunology
Cancer
|
|
Adezmapimod (SB 203580) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride is an autophagy and mitophagy activator.
|
-
- HY-15515
-
|
SEA0400
|
Na+/Ca2+ Exchanger
|
Cardiovascular Disease
|
|
SEA0400 is a novel and selective inhibitor of the Na +-Ca 2+ exchanger (NCX), inhibiting Na +-dependent Ca 2+ uptake in cultured neurons, astrocytes, and microglia with IC50s of from 5 to 33 nM.
|
-
- HY-30237
-
|
Seliciclib
Roscovitine; CYC202; R-roscovitine
|
CDK
|
Cancer
|
|
Seliciclib (Roscovitine) is an orally bioavailable and selective CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
|
-
- HY-N7560
-
|
Safranal
|
Others
|
Inflammation/Immunology
Neurological Disease
|
|
Safranal is an orally active main component of Saffron (Crocus sativus) and is responsible for the unique aroma of this spice. Safranal has neuroprotective and anti-inflammatory effects and has the potential for Parkinson’s disease research.
|
-
- HY-13515
-
-
- HY-12012
-
-
- HY-120494
-
-
- HY-149004
-
-
- HY-15762
-
-
- HY-P1495
-
-
- HY-12297
-
|
Sulfatinib
HMPL-012
|
FGFR
VEGFR
|
Cancer
|
|
Sulfatinib (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC50s of in a range of 1 to 24 nM.
|
-
- HY-16966
-
|
SBI-0206965
|
ULK
Autophagy
Apoptosis
|
Cancer
|
|
SBI-0206965 is a potent, selective and cell permeable autophagy kinase ULK1 inhibitor with IC50s of 108 nM for ULK1 kinase and 711 nM for the highly related kinase ULK2.
|
-
- HY-124876
-
|
SynuClean-D
SC-D
|
α-synuclein
|
Neurological Disease
|
|
SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease.
|
-
- HY-42066
-
-
- HY-135858
-
|
SARS-CoV-IN-3
|
SARS-CoV
Parasite
HIV
|
Infection
|
|
SARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-3 shows anti-Coronavirus activity with an EC50 of 3.6 μM in Vero cells. SARS-CoV-IN-3 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 11.7 and 20.4 nM; and IC90s of 29.19 and 56 nM; respectively. SARS-CoV-IN-3 reduces HIV-1-induced cytopathic effect with an EC50 of 10 μM in MT-4 cells.
|
-
- HY-10256
-
|
Adezmapimod
SB 203580; RWJ 64809
|
p38 MAPK
Autophagy
Mitophagy
|
Inflammation/Immunology
Cancer
|
|
Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator.
|
-
- HY-10201S2
-
|
Sorafenib-13C,d3
|
Raf
VEGFR
FLT3
Autophagy
Apoptosis
Ferroptosis
|
Cancer
|
|
Sorafenib- 13C,d3 is the 13C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].
|
-
- HY-15238A
-
-
- HY-105003
-
|
ST 1535
|
Adenosine Receptor
|
Neurological Disease
|
|
ST 1535 is a potent and orally active A2A adenosine receptor antagonist. ST 1535 shows antiparkinsonian activity and antitremorigenic effects. ST 1535 has the potential for the research of Parkinson’s disease.
|
-
- HY-N1282
-
|
Seneciphylline
|
Gutathione S-transferase
Cytochrome P450
|
Cancer
|
|
Seneciphylline is a toxic pyrrolizidine alkaloid in Gynura japonica. Seneciphylline significantly increases the activities of epoxide hydrase and glutathione-S-transferase but causes reduction of cytochrome P-450 and related monooxygenase activities.
|
-
- HY-111407
-
|
MK-8353
SCH900353
|
ERK
|
Cancer
|
|
MK-8353 (SCH900353) is a potent, selective and orally available ERK1/2 inhibitor, with IC50s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity.
|
-
- HY-100779
-
|
Rimacalib
SMP 114
|
CaMK
Autophagy
|
Metabolic Disease
|
|
Rimacalib (SMP 114) is a Ca 2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor, with IC50s of ~1 μM for CaMKIIα to ~30 μM for CaMKIIγ.
|
-
- HY-102037
-
-
- HY-149004A
-
-
- HY-13250
-
|
Silvestrol aglycone
|
Others
|
Cancer
|
|
Silvestrol aglycone is a Silvestrol analogue, inhibits protein translation initiation in cancer cells, with EC50s of 10 and 200 nM for myc-LUC and tub-LUC luciferase reporter protein translation, respectively. Anti-cancer activity.
|
-
- HY-107414
-
-
- HY-P99952
-
|
Ripertamab
SCT400
|
CD20
|
Cancer
|
|
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL).
|
-
- HY-N0802
-
|
Tenuigenin
Senegenin
|
NF-κB
Bacterial
|
Infection
Inflammation/Immunology
|
|
Tenuigenin is a major active component isolated from the root of the Chinese herb Polygala tenuifolia. Tenuigenin protects against S.aureus-induced pneumonia by inhibiting NF-κB activation. Tenuigenin has anti-inflammatory effect.
|
-
- HY-149048
-
|
Adenosylhomocysteinase
SAHH; AHCY
|
Endogenous Metabolite
HBV
|
Infection
Metabolic Disease
|
|
Adenosylhomocysteinase (SAHH; AHCY) is a highly conserved enzyme. Adenosylhomocysteinase reversible catalyzes S-adenosylhomocysteine (SAH) to adenosine and L-homocysteine. The serum exosomal Adenosylhomocysteinase level can be used as a prognostic biomarker in HBV-LC patients.
|
-
- HY-13768C
-
|
Topotecan hydrochloride hydrate
SKF 104864A hydrochloride hydrate; NSC 609669 hydrochloride hydrate
|
Topoisomerase
Apoptosis
Autophagy
|
Cancer
|
|
Topotecan hydrochloride hydrate is an orally active and potent Topoisomerase I inhibitor. Topotecan hydrochloride hydrate induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan hydrochloride hydrate shows anticancer activity.
|
-
- HY-15776
-
-
- HY-13962
-
-
- HY-79404
-
-
- HY-135856
-
|
SARS-CoV-IN-2
|
SARS-CoV
Parasite
HIV
|
Infection
|
|
SARS-CoV-IN-2 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-2 shows anti-Coronavirus activity with an EC50 of 1.9 μM in Vero cells. SARS-CoV-IN-2 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 21.5 and 30 nM; and IC90s of 51.0 and 99.9 nM; respectively. SARS-CoV-IN-2 reduces HIV-1-induced cytopathic effect with an EC50 of 2.9 μM in MT-4 cells. Antimalarial and Antiviral Activities.
|
-
- HY-138067
-
|
SSAA09E2
|
SARS-CoV
|
Inflammation/Immunology
|
|
SSAA09E2 is an inhibitor of SARS-CoV (Severe acute respiratory syndrome-Coronavirus) replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2) .
|
-
- HY-21292
-
|
SU5214
SU4949
|
VEGFR
|
Cancer
|
|
SU5214 is a potent VEGFR2 inhibitor extracted from patent US5834504A, SU5214, has IC50s of 14.8 µM (FLK-1) and 36.7 µM (EGFR), respectively.
|
-
- HY-10563
-
|
Sarpogrelate
MCI-9042 free acid
|
5-HT Receptor
|
Infection
|
|
Sarpogrelate (MCI-9042) is a new, specific orally active 5-HT2 receptor antagonist, Sarpogrelate increases platelet aggregation and has hemostasis effect, and can be used for the research of Buerger’s disease.
|
-
- HY-123346
-
|
SW155246
|
DNA Methyltransferase
|
Cancer
|
|
SW155246 is a DNA methyltransferase (DNMT1) selective inhibitor with IC50s of 1.2 and 38 μM for hDNMT1 and mDNMT3A, respectively. SW155246 can be used for the research of cancer and other diseases.
|
-
- HY-107658
-
-
- HY-19910
-
|
Acoziborole
SCYX-7158; AN5568
|
Parasite
|
Infection
|
|
Acoziborole (SCYX-7158) is an effective, safe and orally active antiprotozoal agent for the research of human african trypanosomiasis (HAT). In the T. b. brucei S427 strain, the MIC value for SCYX-7158 is 0.6 µg/mL.
|
-
- HY-N8307
-
|
Syringaresinol
|
Others
|
Inflammation/Immunology
Cardiovascular Disease
|
|
Syringaresinol is a lignan that can be extracted from from Dragon’s Blood of Dracaena cambodiana. Syringaresinol has anti-inflammatory activity. Syringaresinol also causes vasorelaxation. Syringaresinol elevates NO production through the phosphorylation and dimerization of endothelial NO synthase.
|
-
- HY-N7046
-
|
Silybin B
|
Amyloid-β
|
Cancer
Neurological Disease
|
|
Silybin B, a flavonolignan separated from Silybum marianum, has anti-tumor activity. Silybin B is the most potent antifibrillogenic and anti-oligomeric component of silymarin and proposes it as a promising anti Alzheimer’s disease drug candidate.
|
-
- HY-10234
-
|
Saracatinib
AZD0530
|
Src
Autophagy
|
Cancer
|
|
Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases.
|
-
- HY-101626A
-
-
- HY-108333
-
|
SB-633825
|
Others
|
Cancer
Cardiovascular Disease
|
|
SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC50s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis.
|
-
- HY-101626
-
|
Sigma-LIGAND-1
|
Sigma Receptor
|
Neurological Disease
|
|
Sigma-LIGAND-1 is a selective sigma receptor ligand with an IC50s of 16 nM, 19 nM at the DTG site and the PPP site, respectively. Sigma-LIGAND-1 has a Ki of 4000 nM at the dopamine D2 receptor.
|
-
- HY-N2560
-
|
Senecionine
Senecionan-11,16-dione, 12-hydroxy-; Aureine; Senecionin
|
Others
|
Metabolic Disease
|
|
Senecionine (Senecionan-11,16-dione, 12-hydroxy-) is a pyrrolizidine alkaloid could be isolated from Senecio vulgaris. Senecionine decreases the activities of glutathione S-transferase, aminopyrine demethylase and arylhydrocarbon hydroxylase (AHH).
|
-
- HY-123475A
-
|
Sisunatovir hydrochloride
RV521 hydrochloride
|
RSV
|
Infection
|
|
Sisunatovir (RV521) hydrochloride, an orally available inhibitor of the RSV fusion (RSV-F) protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM, respectively.
|
-
- HY-148103
-
|
SR12418
|
REV-ERB
|
Inflammation/Immunology
|
|
SR12418 is a REV-ERB-specific synthetic ligand with IC50s of 68 nM and 119 nM for REV-ERBα and REV-ERBβ, respectively. SR12418 can be used in experimental autoimmune encephalomyelitis (EAE) and colitis research.
|
-
- HY-123475
-
|
Sisunatovir
RV521
|
RSV
|
Infection
|
|
Sisunatovir (RV521), an orally available inhibitor of the RSV fusion (RSV-F) protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM, respectively.
|
-
- HY-U00341
-
|
ST4206
|
Adenosine Receptor
|
Neurological Disease
|
|
ST4206 is a potent and orally active adenosine A2A receptor antagonist, with Kis of 12 nM and 197 nM for adenosine A2A receptor and adenosine A1 receptor, respectively. ST4206 has the potential for Parkinson׳s disease research.
|
-
- HY-14958A
-
-
- HY-103226
-
|
SC-57461A
|
Aminopeptidase
|
Inflammation/Immunology
|
|
SC-57461A is a potent, orally active, nonpeptide, and selective inhibitor of Leukotriene A4 (LTA4) hydrolase with IC50s of 2.5 nM, 3 nM, and 23 nM for recombinant human, mouse, and rat LTA4 hydrolase, respectively.
|
-
- HY-14958
-
-
- HY-112713
-
|
SMS2-IN-2
|
Others
|
Inflammation/Immunology
|
|
SMS2-IN-2 is a potent, highly selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with IC50s of 100 nM and 56 μM for SMS2 and SMS1, respectively. Anti-chronic inflammatory activity.
|
-
- HY-13768
-
|
Topotecan
SKF 104864A; NSC 609669
|
Topoisomerase
Autophagy
Apoptosis
|
Cancer
|
|
Topotecan (SKF 104864A; NSC 609669) is an orally active and potent Topoisomerase I inhibitor. Topotecan induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan shows anticancer activity.
|
-
- HY-U00235
-
|
SR121566A
|
Integrin
|
Inflammation/Immunology
|
|
SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively.
|
-
- HY-100224
-
|
SANT-1
|
Smo
Hedgehog
|
Cancer
|
|
SANT-1, a potent Smo antagonist, inhibits Hedgehog signaling. SANT-1 shows IC50s of 20 nM and 30 nM in Shh-LIGHT2 and SmoA1-LIGHT2 assay, respectively.
|
-
- HY-P9807
-
-
- HY-100228A
-
-
- HY-105185
-
|
Fidarestat
SNK 860
|
Aldose Reductase
|
Metabolic Disease
|
|
Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
|
-
- HY-15262
-
|
SRT 2104
|
Sirtuin
|
Metabolic Disease
Neurological Disease
Cancer
|
|
SRT 2104 is a first-in-class, highly selective and brain-permeable activator of the NAD + dependent deacetylase Sirt1, increases Sirt1 protein, but shows no effect on Sirt1 mRNA. Used in the research of diabetes mellitus and Huntington’s disease.
|
-
- HY-126033
-
|
Sophoranol
|
HBV
RSV
|
Infection
|
|
Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratory syncytial virus (RSV) with an IC50 of 10.4 μg/mL.
|
-
- HY-111400
-
|
SR-4370
|
HDAC
|
Cancer
|
|
SR-4370 is an inhibitor of HDAC, with IC50s of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC6, respectively.
|
-
- HY-111388
-
|
SEL120-34A
|
CDK
|
Cancer
|
|
SEL120-34A is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
|
-
- HY-132841A
-
|
Sucunamostat hydrochloride
SCO-792 hydrochloride
|
Others
|
Metabolic Disease
|
|
Sucunamostat (SCO-792) hydrochloride is an orally active and reversible enteropeptidase inhibitor with IC50s of 4.6 nM and 5.4 nM for rat enteropeptidase and human enteropeptidase, respectively. Sucunamostat hydrochloride can slowly dissociate from enteropeptidase in vitro and inhibit protein digestion in vivo.
|
-
- HY-13704
-
|
SN-38
NK012
|
Topoisomerase
ADC Cytotoxin
Autophagy
|
Cancer
|
|
SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively.
|
-
- HY-111388B
-
|
SEL120-34A HCl
|
CDK
|
Cancer
|
|
SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
|
-
- HY-B0400S1
-
|
D-Sorbitol-13C
Sorbitol-13C; D-Glucitol-13C
|
Endogenous Metabolite
|
Others
|
|
D-Sorbitol- 13C is the 13C labeled D-Sorbitol. D-Sorbitol (Sorbitol) is a six-carbon sugar alcohol and can used as a sugar substitute. D-Sorbitol can be used as a stabilizing excipient and/or isotonicity agent, sweetener, humectant, thickener and dietary s
|
-
- HY-10579
-
|
Pluripotin
SC1
|
Ribosomal S6 Kinase (RSK)
ERK
|
Cancer
|
|
Pluripotin is a dual inhibitor of ERK1 and RasGAP with KDs of 98 nM and 212 nM, respectively. Pluripotin also inhibits RSK1, RSK2, RSK3, and RSK4 with IC50s of 0.5, 2.5, 3.3, and 10.0 µM, respectively.
|
-
- HY-144967
-
|
SOS1-IN-13
|
Ras
|
Cancer
|
|
SOS1-IN-13 is a potent son of sevenless homolog 1 (SOS1) inhibitor with IC50s of 6.5 nM and 327 nM for SOS1 and pERK, respectively. SOS1-IN-13 can be used for researching anticancer.
|
-
- HY-101146
-
-
- HY-130126
-
|
Sucunamostat hydrate
SCO-792
|
Others
|
Others
|
|
Sucunamostat hydrate (SCO-792) is an orally active and reversible enteropeptidase inhibitor with IC50s of 4.6 nM and 5.4 nM for rat enteropeptidase and human enteropeptidase, respectively. Sucunamostat hydrate can slowly dissociate from enteropeptidase in vitro and inhibit protein digestion in vivo.
|
-
- HY-15191
-
|
Sabutoclax
BI-97C1
|
Bcl-2 Family
|
Cancer
|
|
Sabutoclax is a potent and effective Bcl-2 Family (Bcl-2, Bcl-XL, Mcl-1, Bfl-1) inhibitor with IC50s of 0.32 μM, 0.31 μM, 0.20 μM, and 0.62 μM, respectively.
|
-
- HY-122825
-
|
SNIPER(ER)-110
|
SNIPERs
Estrogen Receptor/ERR
|
Cancer
|
|
SNIPER(ER)-110 consists of a IAP ligand and an estrogen ligand, connected by a linker. SNIPER(ER)-51 induces estrogen receptor (ER) protein degradation with DC50s of <3 nM and 7.7 nM after 4 h and 48 h, respectively.
|
-
- HY-14877
-
-
- HY-13322
-
|
Pracinostat
SB939
|
HDAC
Apoptosis
|
Cancer
|
|
Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC50s of 40-140 nM, used for cancer research. Pracinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM.
|
-
- HY-16784
-
|
Samatasvir
IDX719; IDX18719
|
HCV
HCV Protease
|
Infection
|
|
Samatasvir (IDX71) is a potent, orally active NS5A inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with EC50s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons.
|
-
- HY-117778
-
-
- HY-101964
-
|
SPI-112
|
SHP2
Phosphatase
|
Cancer
|
|
SPI-112 is a potent, selective and competitive SHP2 (PTPN11) inhibitor with IC50s of 1 μM, 18.3 μM and 14.5 μM for SHP2, protein tyrosine phosphatase (PTP) and PTP1B, respectively.
|
-
- HY-14877A
-
-
- HY-10008
-
|
SNS-032
BMS-387032
|
CDK
Apoptosis
|
Cancer
|
|
SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2, CDK7, and CDK9 with IC50s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect.
|
-
- HY-17034AS
-
|
Dexmedetomidine-13C,d3 hydrochloride
(+)-Medetomidine-13C,d3 (hydrochloride); (S)-Medetomidine-13C,d3 (hydrochloride)
|
Adrenergic Receptor
|
Neurological Disease
Endocrinology
Cancer
|
|
Dexmedetomidine- 13C,d3 (hydrochloride) is the 13C- and deuterium labeled Dexmedetomidine (hydrochloride). Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects[1][2][3].
|
-
- HY-109191A
-
|
Sovesudil hydrochloride
PHP-201 hydrochloride; AMA0076 hydrochloride
|
ROCK
|
Neurological Disease
|
|
Sovesudil (PHP-201) hydrochloride is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC50s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil hydrochloride lowers intraocular pressure (IOP) without inducing hyperemia.
|
-
- HY-109191
-
|
Sovesudil
PHP-201; AMA0076
|
ROCK
|
Others
|
|
Sovesudil (PHP-201) is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC50s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil lowers intraocular pressure (IOP) without inducing hyperemia.
|
-
- HY-151345
-
|
sRANKL-IN-1
|
RANKL/RANK
|
Inflammation/Immunology
|
|
sRANKL-IN-1 (compound S3) is a sRANKL (soluble RANKL) inhibitor. sRANKL-IN-1 shows a potent osteoclast inhibition effect with an IC50 value of 0.096 μM and a KD value of 34.80 μM. sRANKL-IN-1 can be used for the research of osteoporosis.
|
-
- HY-139983
-
|
SDH-IN-1
|
Fungal
|
Infection
|
|
SDH-IN-1 (compound 4i) is a succinate dehydrogenase (SDH) inhibitor with an IC50 of 4.53 μM. SDH-IN-1 has potent antifungal activities. SDH-IN-1 displays potent activity against S. sclerotiorum (EC50 of 0.14 mg/L).
|
-
- HY-50846
-
|
SCH772984
|
ERK
|
Cancer
|
|
SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC50s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-naïve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations.
|
-
- HY-16661
-
|
Skp2 Inhibitor C1
SKPin C1
|
E1/E2/E3 Enzyme
|
Cancer
|
|
Skp2 Inhibitor C1 (SKPin C1) is an S-phase kinase-related protein 2 (Skp2) inhibitor with an inhibitory effect on metastatic melanoma cells. Skp2 Inhibitor C1 slows the cell cycle, inhibits cell proliferation, and triggers apoptosis.
|
-
- HY-12041
-
|
SP600125
|
JNK
Autophagy
Apoptosis
Ferroptosis
|
Cancer
|
|
SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 inhibits autophagy and activates apoptosis.
|
-
- HY-119375
-
|
Syncytial Virus Inhibitor-1
|
Bacterial
|
Infection
|
|
Syncytial Virus Inhibitor-1 is a potent, orally bioavailable respiratory syncytial virus (RSV) fusion inhibitor with EC50s of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively.
|
-
- HY-111678
-
|
ML230
CID44640177; SID 88095709
|
BCRP
|
Cancer
|
|
ML230 (CID44640177; SID 88095709) is a selective inhibitor of ATP-binding cassette (ABC) transporter ABCG2, and 36-fold selective for ABCG2 over ABCB1 with EC50s values of 0.13 μM and 4.65 μM, respectively.
|
-
- HY-15834A
-
|
Eprosartan mesylate
SKF-108566J
|
Angiotensin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Eprosartan mesylate (SKF-108566J) is a selective, competitive, nonpeptid and orally active angiotensin II receptor antagonist, used as an antihypertensive. Eprosartan mesylate binds angiotensin II receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively.
|
-
- HY-150513
-
|
SLP9101555
|
SphK
|
Cancer
|
|
SLP9101555 (compound 14c) is a potent and selective SphK2 (sphingosine kinase 2) inhibitor (Ki=90 nM) with 200-fold selectivity over SphK1. SLP9101555 markedly decreases extracellular S1P (sphingosine 1-phosphate) levels.
|
-
- HY-15762S
-
|
Valdecoxib-d3
SC 65872-d3
|
COX
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Valdecoxib-d3 is the deuterium labeled Valdecoxib. Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain[1][2].
|
-
- HY-N1196
-
|
Suberosin
|
NF-κB
|
Inflammation/Immunology
|
|
Suberosin, isolated from Plumbago zeylanica, exhibits anti-inflammatory and anticoagulant activity. Suberosin suppresses PHA-induced PBMC proliferation and arrested cell cycle progression from the G1 transition to the S phase through the modulation of the transcription factors NF-AT and NF-κB.
|
-
- HY-13858A
-
|
Sarecycline hydrochloride
|
Antibiotic
Bacterial
DNA/RNA Synthesis
|
Infection
|
|
Sarecycline hydrochloride is a narrow-spectrum tetracycline-class antibiotic. Sarecycline hydrochloride possesses anti-inflammatory properties and potent activity against Gram-positive bacteria, including activity against multiple strains of Cutibacterium acnes. Sarecycline hydrochloride interferes with tRNA accommodation and tethers mRNA to the 70S ribosome.
|
-
- HY-P99044
-
|
Sabatolimab
MBG453
|
Tim3
|
Inflammation/Immunology
|
|
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells.
|
-
- HY-12418
-
|
Stenoparib
E7449; 2X-121
|
PARP
|
Cancer
|
|
E7449 is a potent PARP1 and PARP2 inhibitor and also inhibits TNKS1 and TNKS2, with IC50s of 2.0, 1.0, ∼50 and ∼50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using 32P-NAD + as substrate.
|
-
- HY-B0789
-
|
SU6656
|
Src
FAK
Akt
|
Cancer
|
|
SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.
|
-
- HY-117743
-
|
Eprosartan
SKF-108566J free base
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active angiotensin II receptor antagonist, used as an antihypertensive. Eprosartan binds angiotensin II receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively .
|
-
- HY-103200
-
-
- HY-10255A
-
|
Sunitinib
SU 11248
|
VEGFR
PDGFR
IRE1
Mitophagy
Autophagy
Apoptosis
|
Cancer
|
|
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
|
-
- HY-100672
-
-
- HY-126326
-
|
SWE101
|
Epoxide Hydrolase
|
Metabolic Disease
|
|
SWE101 (compound 22 b) is a potent soluble epoxide hydrolase (sEH)-P inhibitor with IC50s of 4 μM and 2.8 μM for human and rat sEH-P, respectively. SWE101 does not inhibit neither hydrolase nor phosphatase activity of the mouse sEH.
|
-
<
